An assessment conducted in November 2013 put Evidence-based Series (EBS) 8-5 Version 2 in the Education and Information. This means that the recommendations will no longer be maintained by may still be useful for academic or other information purposes. The PEBC has a formal and standardized process to ensure the currency of each document (PEBC Assessment & Review Protocol).

**Evidence-based Series (EBS) 8-5 Version 2**, the resulting review report, consists of the following 5 parts:

1. Guideline Report Overview
2. Section 1: Clinical Practice Guideline
3. Section 2: Systematic Review
4. Section 3: Guideline Development and External Review
5. Document Assessment and Review Tool

and is available on the CCO website (http://www.cancercare.on.ca)

PEBC Melanoma DSG page at:
http://www.cancercare.on.ca/toolbox/qualityguidelines/diseasesite/melanoma-eps/

**Release Date:** September 15, 2011

For information about the PEBC and the most current version of all reports, please visit the CCO website at http://www.cancercare.on.ca or contact the PEBC office at:
Phone: 905-527-4322 ext. 42822 Fax: 905-526-6775 E-mail: ccopgi@mcmaster.ca

**Journal Citation (Vancouver Style):**

# TABLE OF CONTENTS

## OVERVIEW
Guideline Report History ........................................................................................................ iii
Guideline Review Summary ...................................................................................................... iv

## SECTION 1: Clinical Practice Guideline
Questions ................................................................................................................................... 1
Recommendations ....................................................................................................................... 1
Qualifying Statements ............................................................................................................... 2
Related Guidelines ..................................................................................................................... 3
Funding, Copyright, Disclaimer, & Contact information .......................................................... 3

## SECTION 2: Systematic Review
Question ..................................................................................................................................... 1
Introduction ............................................................................................................................... 1
Methods ..................................................................................................................................... 2
Results ....................................................................................................................................... 3
Discussion ................................................................................................................................. 18
Ongoing Trials .......................................................................................................................... 19
Conclusion ................................................................................................................................. 20
Conflict of Interest .................................................................................................................... 20
Journal References ................................................................................................................... 20
Acknowledgements .................................................................................................................. 20
Funding, Copyright, Disclaimer, & Contact information .......................................................... 20
References ................................................................................................................................. 21

## SECTION 3: Guideline Development and External Review
The Program in Evidence-Based Care ....................................................................................... 1
Development of this Evidence-based Series ............................................................................ 2
Funding, Copyright, Disclaimer, & Contact information .......................................................... 6
References ................................................................................................................................. 8
Appendix 1: EBS 8-5 Document Assessment and Review Tool .................................................. 9
Evidence-based Series 8-5 Version 2

Single-Agent Interleukin-2 in the Treatment of Metastatic Melanoma

Guideline Report History

<table>
<thead>
<tr>
<th>GUIDELINE VERSION</th>
<th>SYSTEMATIC REVIEW</th>
<th>PUBLICATIONS</th>
<th>NOTES AND KEY CHANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original version</td>
<td>Search Dates</td>
<td>Data</td>
<td>Peer review publication¹,²</td>
</tr>
<tr>
<td>March 2006</td>
<td>1985 to 2006</td>
<td>Full Report</td>
<td>Web publication</td>
</tr>
<tr>
<td>Version 2</td>
<td>2006 to 2010</td>
<td>New data found in Document Assessment &amp; Review Tool</td>
<td>Updated Web publication</td>
</tr>
<tr>
<td>Sep 2011</td>
<td></td>
<td></td>
<td>Guideline recommendations ENDORSED</td>
</tr>
</tbody>
</table>

Evidence-based Series 8-5 Version 2

Single-Agent Interleukin-2 in the Treatment of Metastatic Melanoma

Guideline Review Summary

Review Date: August 4, 2010

The 2006 guideline recommendations are ENDORSED

This means that the recommendations are still current and relevant for decision making.

OVERVIEW

Evidence-based Series History

This guidance document was originally released by the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO), in 2006. In June 2010, the PEBC guideline update strategy was applied and the new updated document released in September 2011. The Practice Guideline and the Systematic Review in this version are the same as in the March 2006 version.

Update Strategy

Using the Document Assessment & Review Tool, the PEBC update strategy includes an updated search of the literature, review and interpretation of the new eligible evidence by clinical experts from the authoring guideline panel, and consideration of the guideline and its recommendations in response to the new available evidence.

DOCUMENT ASSESSMENT AND REVIEW RESULTS

Questions Considered

1. What is the role of single-agent interleukin-2 (IL-2) in the treatment of adults with metastatic melanoma? Primary outcomes of interest include objective response rates, complete response rates, duration of response, toxicity, and quality of life. Secondary outcomes of interest include progression-free survival and overall survival.

2. If there is a role for single-agent IL-2, what is the appropriate patient population to be considered for treatment?

3. If there is a role for single-agent IL-2, what is the appropriate dose and schedule?
4. What are the toxicities associated with IL-2?

**Literature Search and New Evidence**

The new search (March 2006 to June 2010) yielded eight relevant new publications (six abstracts and two full text publications) of eight studies, including one RCT. Results of these publications are shown in the Document Assessment & Review Tool at the end of this report.

**Impact on Guidelines and Its Recommendations**

The new data supports existing recommendations for EBS 8-5; therefore, the Melanoma DSG ENDORSED the 2006 recommendations on single-agent interleukin-2 in the treatment of metastatic melanoma.
Questions
1. What is the role of single-agent interleukin-2 (IL-2) in the treatment of adults with metastatic melanoma? Primary outcomes of interest include objective response rates, complete response rates, duration of response, toxicity, and quality of life. Secondary outcomes of interest include progression-free survival and overall survival.
2. If there is a role for single-agent IL-2, what is the appropriate patient population to be considered for treatment?
3. If there is a role for single-agent IL-2, what is the appropriate dose and schedule?
4. What are the toxicities associated with IL-2?

Recommendations
- There are no studies that compare IL-2 to the current standard of care, dacarbazine (DTIC), or to placebo in the treatment of metastatic melanoma.
- After weighing and reviewing the evidence that does exist, the opinion of the Melanoma Disease Site Group is that high-dose IL-2 is a reasonable treatment option for a select group of patients with metastatic melanoma:
  - Patients should have a good performance status (Eastern Cooperative Oncology Group [ECOG] 0-1), and a normal lactate dehydrogenase (LDH) level.
Patients should have less than three organs involved or have cutaneous and/or subcutaneous metastases only and no evidence of central nervous system metastases. In this select group of patients IL-2 treatment can produce durable complete remissions.

- The recommended dose and schedule of high-dose IL-2 is 600,000 IU/kg/dose intravenously over 15 minutes, every eight hours, for a maximum of 14 doses.
- If high-dose IL-2 is delivered, the recommendation is that it be done in a tertiary care facility with staff trained in the provision of this treatment with appropriate monitoring.
- To facilitate patient treatment and develop expertise in this therapeutic modality, the recommendation is that high-dose IL-2 programs be established in one or two centres in Ontario.

Qualifying Statements

- High dose IL-2 has similar response rates to our standard chemotherapy; however the low but durable complete response seen with IL-2 is very rare with chemotherapy and may lead to years of benefit for patients.
- Based on the available data assessing prognostic factors and patient selection, patients with non-visceral metastases and fewer metastatic sites have a much higher response rate. In these select patients, high dose Interleukin-2 may be considered first line therapy.
- Recommendations for this guideline are based largely on phase II data and very little phase III data due to the lack of availability of large randomized trials comparing IL-2 to DTIC or other chemotherapy. Further randomized data will not be available as there are currently no ongoing or planned randomized trials. IL-2 is currently widely used in the United States and is an approved therapy in both Canada and the United States.

Key Evidence

- There are no randomized controlled trials that compare high-dose IL-2 to the current standard of care, DTIC.
  - The only randomized controlled trials conducted to date have compared high-dose single-agent IL-2 to high-dose IL-2 in combination with either interferon or lymphokine-activated killer cells.
  - Data from three randomized controlled trials has demonstrated that single-agent IL-2, when given in high doses, can elicit an objective response rate of 5% to 27% with complete responses in 0% to 4% of patients.
  - Similarly several noncomparative phase II trials of high-dose single-agent IL-2 have consistently reported objective response rates of 10% to 33% with complete responses ranging from 0% to 15%.
  - High-dose IL-2, as a single agent or in combination with lymphokine-activated killer (LAK) cells, can elicit long-term responses in select patients.
  - The three randomized trials demonstrate that in the 0% to 11% of patients, who are complete responders, there have been consistent observations of long-term responses that range from 6 to 66+ months (median 27 months).
  - Complete responders in phase II trials have also demonstrated impressive long-term responses that range from 1.5 to 148 months (median 70 months).
  - No other therapy for metastatic melanoma offers the possibility for a durable complete remission.
- Several trials have investigated factors associated with response to IL-2. Those data show that carefully selected patients have the highest chance of response. Patients with a good performance status (ECOG 0-1) and a normal LDH level, as well as with less than three organs involved or cutaneous and/or subcutaneous metastases only have the highest
probability of responding and achieving a durable complete response. That carefully
selected group of patients should be considered for treatment with high-dose IL-2.

- The recommended dose and schedule of high-dose IL-2 is supported by the majority of
trials as well as the National Cancer Institute.
  - The majority of trials of high-dose single-agent IL-2 used a dose and schedule of
    600,000 IU/kg/dose intravenously over 15 minutes, every eight hours, for a maximum
    of 14 doses. The National Cancer Institute published guidelines for the safe
    administration of high-dose IL-2 in 2001 and recommended the above dose and
    schedule. In addition, the United States Food and Drug Administration approved the
    use of IL-2 for the treatment of patients with metastatic melanoma at that same dose
    and schedule.

- High-dose IL-2 should be delivered in a tertiary care facility with staff trained in the
  provision of this treatment with appropriate monitoring.
  - High-dose IL-2 therapy has considerable grade 3/4 toxicity. Three randomized
    controlled trials of high-dose IL-2 and eight noncomparative phase II trials of single-
    agent high-dose IL-2 have reported the following types of grade 3/4 adverse effects:
    gastrointestinal (range 0-76%), cardiovascular (range 0-74%), renal (range 0-87%),
    neurologic (range 0-29%), hematologic (range 0-71%), febrile neutropenia (range 4-
    88%), sepsis (range 0-63%) and hepatic (0-90%). Those toxicities are manageable with
    the use of available guidelines and trained staff.

Related Guidelines

The Program in Evidence-based Care’s:

- Evidence-based Series Report #8-3: Biochemotherapy for the Treatment of Metastatic
  Malignant Melanoma. Please note that this guideline is currently under development and
  is not yet available on the Web site.

- Evidence-based Series Report #8-4: Single-agent Temozolomide for the Treatment of
  Metastatic Melanoma. Please note that this guideline is currently under development and
  is not yet available on the Web site.

Funding

The PEBC is supported by Cancer Care Ontario (CCO) and the Ontario Ministry of Health and Long-Term
Care. All work produced by the PEBC is editorially independent from its funding agencies.

Copyright

This evidence-based series is copyrighted by Cancer Care Ontario; the series and the illustrations
herein may not be reproduced without the express written permission of Cancer Care Ontario. Cancer
Care Ontario reserves the right at any time, and at its sole discretion, to change or revoke this
authorization.

Disclaimer

Care has been taken in the preparation of the information contained in this document. Nonetheless,
any person seeking to apply or consult the evidence-based series is expected to use independent
medical judgment in the context of individual clinical circumstances or seek out the supervision of a
qualified clinician. Cancer Care Ontario makes no representation or guarantees of any kind whatsoever
regarding their content or use or application and disclaims any responsibility for their application or
use in any way.

Contact Information

For further information about this Evidence-based Series, please contact:
Dr. Ian Quirt, Co-Chair, Melanoma Disease Site Group, Princess Margaret Hospital, 610 University Avenue, Toronto ON, M5G 2M9; TEL 416-946-2249; FAX 416-946-6546
or
Dr. Shail Verma, Co-Chair, Melanoma Disease Site Group, Integrated Cancer Program at The Ottawa Hospital - General Campus, 503 Smyth Road, Ottawa, ON, K1H 1C4; TEL 613-737-7700; FAX 613-247-3511.

For information about the PEBC and the most current version of all reports, please visit the CCO Web site at http://www.cancercare.on.ca/ or contact the PEBC office at:
Phone: 905-527-4322 ext. 42822  Fax: 905-526-6775  E-mail: ccopgi@mcmaster.ca
证据系列 #8-5: 第二部分

单药干扰素-2在治疗转移性黑色素瘤中的作用：系统性回顾

T. Petrella, I. Quirt, S. Verma, A. Haynes, M. Charette, K. Bak，以及黑色素瘤疾病小组的成员

一个质量倡议的证据基于护理计划（PEBC），癌症护理安大略（CCO）

开发由黑色素瘤疾病小组

请参阅 EBS 8-5 版本 2 指南回顾摘要和文档评估与审查工具

报告日期：2006年3月20日

问题
1. 单药干扰素-2 (IL-2) 在治疗有转移性黑色素瘤的成年患者中的作用是什么？主要研究结果包括客观响应率、完全响应率、持续响应时间、毒性以及生活质量 (QOL)。
2. 如果有单药 IL-2 的作用，哪些患者应被考虑为治疗对象？
3. 如果有单药 IL-2 的作用，什么样的剂量和方案是合适的？
4. IL-2 相关的毒性是什么？

引言
黑色素瘤的发病率持续增加。2004 年，加拿国有大约 4200 例黑色素瘤，男性和女性的终生风险分别约为 1/80 和 1/94 (1)。虽然早期检测、适当手术和辅助治疗已改善了结果，但至少有三分之一的早期期疾病患者会发展成转移。转移性黑色素瘤的中位生存期为六到八个月，只有 5% 的患者生存超过五年。许多药物已被研究用于治疗黑色素瘤，但很少有药物的响应率超过 10%。达卡巴嗪（DTIC）与替莫唑胺（Temozolomide）进行了比较。
Dartmouth regimen (DTIC, cisplatin, carmustine, and tamoxifen) and to DTIC plus antisense therapy in three large randomized trials (2-4). To date, DTIC has not been compared to best supportive care. When compared to the Dartmouth regimen, DTIC had an overall response rate of 10.2% compared to 18.5% with the Dartmouth regimen (2). However, that result was not statistically significant (p=0.09), and there were no complete responders. Overall survival and median survival did not differ in the two arms (2). DTIC has also been compared to temozolomide (3), with a response rate of 12.1% versus 13.5% with temozolomide, a 3% complete response rate in both arms, a similar duration of response, and no difference in survival. A recently published abstract (4), that was the largest randomized study with DTIC published to date, with 771 patients, compared DTIC to DTIC with BCL-2 antisense. The overall response rate for single-agent DTIC was only 6.8% compared to 11.7% for DTIC plus BCL-2 antisense, however no real difference in survival was reported. The data from those three trials have made DTIC the accepted standard; however, response rates are low, durable responses are rare, and an impact on survival has never been shown. There is universal agreement that further research is critically needed.

Systemic approaches that have been systematically evaluated to date for metastatic disease include cytotoxic chemotherapy (single-agent and multi-drug combinations), vaccines, biochemotherapy, and cytokines such as interferon and IL-2. The latter, single-agent IL-2, has attracted much attention over the past several years. A number of randomized trials and many phase II trials have been completed and their results reported. Those results have generated much interest, particularly the durability of response in complete responders. Given the dismal survival of patients with metastatic melanoma and the limited availability of effective treatments, that durability of response with IL-2 treatment warranted closer examination of this approach by the Melanoma Disease Site Group (DSG).

METHODS
This systematic review was developed by Cancer Care Ontario’s Program in Evidence-based Care (PEBC). Evidence was selected and reviewed by two members of the PEBC Melanoma DSG and methodologists.

This systematic review is a convenient and up-to-date source of the best available evidence on IL-2 in metastatic melanoma. The body of evidence in this review is primarily comprised of mature randomized controlled trial data. That evidence forms the basis of the clinical practice guideline (Section 1) developed by the Melanoma DSG. The systematic review and companion practice guideline are intended to promote evidence-based practice in Ontario, Canada. The PEBC is editorially independent of Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care.

Literature Search Strategy
Searches were performed in the following databases: MEDLINE (1985 through March week 5, 2006), EMBASE (1985 through 2006 week 14), and the Cochrane Library (2006, Issue 1). “Melanoma” (Medical Subject Heading (MeSH) and text word) was combined with “interleukin-2” (MeSH and text word) or “IL-2” (text word). Those terms were then combined with search terms to locate practice guidelines, systematic reviews, meta-analyses, randomized controlled trials, and phase II trials.

In addition, the proceedings of the annual meeting of the American Society of Clinical Oncology (1997-2005) were searched for reports of newly completed or ongoing trials. Relevant articles and abstracts were selected and reviewed by two reviewers, and the reference lists from those sources were searched for additional trials, as were the reference lists from relevant review articles.
Inclusion Criteria
The following types of articles were selected for inclusion in this systematic review of the evidence:
1. Full reports or abstracts of randomized controlled trials or randomized phase II trials in which one trial arm involved single-agent IL-2 for patients with metastatic melanoma.
2. Full reports or abstracts of single-arm phase II trials of single-agent IL-2 for patients with metastatic melanoma, which were included because insufficient evidence was available from randomized controlled trials.
3. Meta-analyses of randomized controlled trials, systematic reviews and evidence-based practice guidelines.

Exclusion Criteria
1. Papers published in a language other than English were not considered due to limited resources for translation.
2. Phase I studies were not considered.
3. Reports that provided data for a sample of less than 10 patients with metastatic melanoma were excluded.

Synthesizing the Evidence
None of the randomized controlled trials compared single-agent IL-2 to standard therapy or to placebo. In addition, the randomized controlled trials included different regimens and doses of IL-2 as well as combining IL-2 with different agents (lymphokine-activated killer cells, interferon, and histamine dihydrochloride). Due to the heterogeneity between the randomized controlled trials, the Melanoma DSG decided against conducting a meta-analysis of the results.

RESULTS
Literature Search Results
One systematic review (5), five randomized trials comparing single-agent IL-2 versus IL-2 combination therapy (6-10) and 12 single arm phase II trials (11-23) were eligible for inclusion in this systematic review of the evidence. In addition, one QOL report for patients included in one of the randomized trials was identified (24).

Systematic Review
One systematic review with meta-analysis reported by Allen et al (5) was identified that evaluated the efficacy and safety of IL-2, chemotherapy, IL-2 + chemotherapy, IL-2 + interferon, and IL-2 + chemotherapy + interferon (biochemotherapy) for patients with metastatic melanoma. Medline, Cancerlit and Current Contents® databases were searched and 154 fully published papers or published abstracts were located and analyzed for response, duration of response, and median survival. Comparative arms were included in eleven studies however not all were randomized. Data extracted from the treatment arms of multiple studies was pooled in a meta-analysis using both fixed and random effects models. Begg’s hierarchical Bayes model was used to estimate the proportions of patients with CR or PR. The rate difference (RD) in response between treatment arms was calculated for nonrandomized, controlled studies with a comparator treatment arm. For uncontrolled studies the rate difference was estimated using Begg’s Bayesian meta-analysis techniques. Sensitivity analyses were carried out using a logistic regression model to examine the influence of study level covariates on efficacy. The pooled results were weighted by treatment arm size and the efficacy outcomes of interest were calculated on an intent-to-treat basis.
A total of 3,285 eligible patients were enrolled in 97 treatment arms of IL-2 as either a single agent, or in combination with chemotherapy, interferon, or biochemotherapy. The pooled objective response rate (complete response + partial response), in this patient population, was 24.6%, with a median duration of response of 8.2 months and a median overall survival of 9.6 months. The review authors also reported data on only 710 patients (23 treatment arms) who received single-agent IL-2. The pooled objective response rate was 14.3%, with a median duration of response of 8.0 months and median survival of 8.1 months. The authors concluded that objective response was significantly improved for IL-2 + chemotherapy or biochemotherapy compared to chemotherapy alone, single-agent IL-2, or IL-2 + interferon (Risk Difference, 16.7% ± 0.012, p<0.001). For the IL-2 + biochemotherapy regimen, high-dose IL-2 significantly improved objective response compared to low-dose IL-2 (45% versus 37%, respectively, p=0.010).

The systematic review reported by Allen et al (5) was complete, however, only up to September 1996. Additional trials of IL-2 including one randomized trial of low-dose IL-2 and several single-arm phase II trials of single-agent IL-2 have been published since the publication of that systematic review. Those new trials contain additional evidence that has not yet been analyzed together with the previously available evidence.

**Randomized Trials**

**Trial Characteristics**

No randomized trials of IL-2 alone compared to placebo or standard treatment were identified. Five randomized controlled trials of IL-2 alone, compared to IL-2 combination therapy were eligible for inclusion in this systematic review. Three randomized trials examined high-dose IL-2 (6–8), with doses of IL-2 ranging from 100,000 IU/kg to 6 MIU/m² given intravenously over 15 minutes every 8 hours. One randomized trial examined low-dose IL-2 (9), administered subcutaneously at 2 and 9 MIU/m². The final randomized trial examined IL-2 at a dose of 3 MIU/m² administered as a continuous intravenous infusion (10). The specific regimens for each trial are shown in Table 1.

**Table 1. Randomized trials of IL-2: regimens.**

<table>
<thead>
<tr>
<th>First author, year (ref)</th>
<th># patients (enrolled / evaluable)</th>
<th>IL-2 Regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Trials of High-dose IL-2</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sparano, 1993 (6)</td>
<td>44/44</td>
<td>IL-2: 6 MIU/m² iv (15min) q8hr d1-5,15-19 (max. 28 doses)</td>
</tr>
<tr>
<td></td>
<td>41/41</td>
<td>IL-2: 4.5 MIU/m² iv (15min) q8hr d1-5,15-19</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IFN: 3 MIU/m² iv (15min) q8hr d1-5,15-19</td>
</tr>
<tr>
<td>Rosenberg, 1993 (7) NCI</td>
<td>26/22</td>
<td>IL-2: 720,000 IU/kg iv q8hr d1-5,11-15</td>
</tr>
<tr>
<td></td>
<td>28/27</td>
<td>IL-2: as above</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LAK: iv d11-15</td>
</tr>
<tr>
<td>McCabe, 1991 (8) [abstract]</td>
<td>46/45</td>
<td>IL-2: 100,000 IU/kg iv q8hr d1-5,11-15</td>
</tr>
<tr>
<td></td>
<td>52/49</td>
<td>IL-2: as above</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LAK: d11,12,14</td>
</tr>
<tr>
<td><strong>Trials of Low-dose IL-2</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>153/153</td>
<td>IL-2: 9 MIU/m² sc bid d1,2 weeks 1,3; 2 MIU/m² sc bid d1-5 weeks 2,4</td>
</tr>
</tbody>
</table>
The characteristics of patients included in the randomized trials of IL-2 are shown in Table 2. Performance status was reported in all five randomized trials of IL-2 except for the trial reported by Richards et al (10). All three trials of high-dose IL-2 used the Eastern Cooperative Oncology Group (ECOG) performance status scale. Two trials included patients with ECOG PS 0-1 (6,8) and one trial included ECOG PS 0-2 (7). The randomized trial of low-dose IL-2 reported by Agarwala et al (9) used the World Health Organization (WHO) scale, with patients having PS 0-1.

Two trials reported on prior treatment for patients with melanoma (6,9). Prior chemotherapy was given to 22% to 26% of patients. Sparano et al (6) also reported that patients received prior immunotherapy and/or radiation therapy. Only two trials reported the sites of metastases (6,9). The most common sites were the lungs, liver, skin, soft tissue, and lymph nodes. Other sites of metastatic disease included bone, central nervous system, and abdomen. Lactate dehydrogenase was reported only in the low-dose IL-2 trial by Agarwala et al (9). All patients included in the trials of high-dose IL-2 were treated as in-patients (6-8). Conversely, patients included in the trial of low-dose IL-2 were treated as out-patients (9).

Table 2. Randomized trials of IL-2: Patient characteristics.

<table>
<thead>
<tr>
<th>First author, year (ref)</th>
<th>Trt Arms (# eval pts)</th>
<th>Performance status (% of pts.)</th>
<th>Median Age (years)</th>
<th>Prior treatment specifics (% of pts)</th>
<th>Sites of metastases (% of pts)</th>
<th>LDH Level*</th>
<th>In/out-patient</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Trials of High-dose IL-2</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sparano, 1993 (6)</td>
<td>IL-2 (44)</td>
<td>ECOG 0, 66% ECOG 1, 34%</td>
<td>50</td>
<td>IMT, 5% CT, 23% RT, 18%</td>
<td>Skin, soft tissue, lymph nodes, 25%; lung, 23%; liver, 52%</td>
<td>NR</td>
<td>In-patient</td>
</tr>
<tr>
<td></td>
<td>IL-2 + IFN (41)</td>
<td>ECOG 0, 61% ECOG 1, 39%</td>
<td>50</td>
<td>IMT, 7% CT, 22% RT, 24%</td>
<td>Skin, soft tissue, lymph nodes, 32%; lung, 29%; abdomen, 14%; liver, 25%</td>
<td>NR</td>
<td>In-patient</td>
</tr>
<tr>
<td>Rosenberg, 1993 (7) NCI</td>
<td>IL-2 (22)</td>
<td>ECOG 0-2</td>
<td>NR</td>
<td>Melanoma pts NR</td>
<td>NR</td>
<td>NR</td>
<td>In-patient</td>
</tr>
<tr>
<td></td>
<td>IL-2 + LAK (27)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: bid = twice daily; d = day(s); hr = hour(s); IFN = interferon; IL-2 = interleukin-2; IU = International U; iv = intravenous; civ = continuous intravenous infusion; LAK = lymphokine-activated killer cells; max. = maximum; min = minutes; MIU = Million International Units; NCI = National Cancer Institute; NR = not reported; q = every; ref = reference; sc = subcutaneously.

a Includes other cancer types; information in tables is for melanoma only.

b Reports on a subgroup of patients also included in the Atkins trial (13,14). Dose indicated in this trial differs from the dose indicated in the Atkins trial.

The characteristics of patients included in the randomized trials of IL-2 are shown in Table 2. Performance status was reported in all five randomized trials of IL-2 except for the trial reported by Richards et al (10). All three trials of high-dose IL-2 used the Eastern Cooperative Oncology Group (ECOG) performance status scale. Two trials included patients with ECOG PS 0-1 (6,8) and one trial included ECOG PS 0-2 (7). The randomized trial of low-dose IL-2 reported by Agarwala et al (9) used the World Health Organization (WHO) scale, with patients having PS 0-1.

Two trials reported on prior treatment for patients with melanoma (6,9). Prior chemotherapy was given to 22% to 26% of patients. Sparano et al (6) also reported that patients received prior immunotherapy and/or radiation therapy. Only two trials reported the sites of metastases (6,9). The most common sites were the lungs, liver, skin, soft tissue, and lymph nodes. Other sites of metastatic disease included bone, central nervous system, and abdomen. Lactate dehydrogenase was reported only in the low-dose IL-2 trial by Agarwala et al (9). All patients included in the trials of high-dose IL-2 were treated as in-patients (6-8). Conversely, patients included in the trial of low-dose IL-2 were treated as out-patients (9).

Table 2. Randomized trials of IL-2: Patient characteristics.

<table>
<thead>
<tr>
<th>First author, year (ref)</th>
<th>Trt Arms (# eval pts)</th>
<th>Performance status (% of pts.)</th>
<th>Median Age (years)</th>
<th>Prior treatment specifics (% of pts)</th>
<th>Sites of metastases (% of pts)</th>
<th>LDH Level*</th>
<th>In/out-patient</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Trials of High-dose IL-2</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sparano, 1993 (6)</td>
<td>IL-2 (44)</td>
<td>ECOG 0, 66% ECOG 1, 34%</td>
<td>50</td>
<td>IMT, 5% CT, 23% RT, 18%</td>
<td>Skin, soft tissue, lymph nodes, 25%; lung, 23%; liver, 52%</td>
<td>NR</td>
<td>In-patient</td>
</tr>
<tr>
<td></td>
<td>IL-2 + IFN (41)</td>
<td>ECOG 0, 61% ECOG 1, 39%</td>
<td>50</td>
<td>IMT, 7% CT, 22% RT, 24%</td>
<td>Skin, soft tissue, lymph nodes, 32%; lung, 29%; abdomen, 14%; liver, 25%</td>
<td>NR</td>
<td>In-patient</td>
</tr>
<tr>
<td>Rosenberg, 1993 (7) NCI</td>
<td>IL-2 (22)</td>
<td>ECOG 0-2</td>
<td>NR</td>
<td>Melanoma pts NR</td>
<td>NR</td>
<td>NR</td>
<td>In-patient</td>
</tr>
<tr>
<td></td>
<td>IL-2 + LAK (27)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Outcome: response

Tumour response data as reported in the randomized trials of IL-2 can be found in Table 3. None of the randomized trials of IL-2 reported a significant difference in objective response rate between the treatment arms. The objective response rate for IL-2 alone ranged from 5%-27% in the trials of high-dose IL-2 (6-8). Low-dose IL-2 elicited an objective response rate of 2% in the trial reported by Agarwala et al (9), and IL-2 administered as a continuous intravenous infusion elicited an objective response rate of 9% (10). The objective response rate for IL-2 in combination with lymphokine-activated killer cells (LAK), interferon, or histamine dihydrochloride (HD) ranged from 5%-22%. The complete response rate for IL-2 alone or in combination ranged from 0-11%. None of the trials reported time to response data.

Sparano et al (6) reported median duration of response as 11.5 months (range, 2.0-15.7+ months). None of the other randomized trials reported data on duration of objective response. Rosenberg et al (7) reported that the patients in IL-2 alone arm had no complete responses while three patients who received IL-2 + LAK demonstrated complete responses with durations ranging from 52+ to 66+ months. McCabe et al (8) reported that two patients in the single agent IL-2 arm had complete responses with durations of six and 12 months. Three patients in the IL-2 + LAK arm also had complete responses with durations of 9, 24+ and 29+ months.

No trial reported data on median time to progression. However, Agarwala et al (9) reported that median time to progression was significantly longer for low-dose IL-2 + HD compared to low-dose IL-2 alone (p=0.038), although the actual median time to progression was not reported.

### Outcome: overall survival

Survival data for patients in the randomized trials of IL-2 can be found in Table 3. Overall survival was reported in two of the high-dose IL-2 trials (6, 7) and in the low-dose IL-2...
None of the trials reported statistically significant differences in overall survival between the treatment arms.

In the Sparano et al (6) trial patients receiving single agent IL-2 demonstrated a median survival of 10.2 months while patients receiving the IL-2/IFN combination treatment showed a median survival of 9.7 months. Rosenberg et al (7) reported a trend towards improved survival for melanoma patients treated with IL-2 plus LAK cells compared to patients treated with single agent IL-2. The two year survival for patients treated with IL-2 plus LAK cells was 32% versus 15% for patients treated with single agent IL-2. Four year survival for this population was reported to be 18% and 4%, respectively. However, the validity of this trend needs to be tested with a larger patient population.

A survival trend was also noted in the low dose trial reported by Agarwala et al (9), however a statistically significant difference was not observed. Although a subgroup analysis of melanoma patients with liver involvement has demonstrated a statistically significant survival benefit for patients treated with IL-2 in combination with histamine (p = 0.008).

Table 3. Randomized trials of IL-2: tumour response and overall survival.

<table>
<thead>
<tr>
<th>First author, year (ref)</th>
<th>Arms</th>
<th># of eval pts</th>
<th>CR/PR (# of pts)</th>
<th>Objective response rate (CR +PR)</th>
<th>Median duration of response (CR + PR) (mos)</th>
<th>Duration of CR (mos)</th>
<th>Median survival (mos)</th>
<th>Median time to progression (mos)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Trials of High-dose IL-2</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sparano, 1993 (6) IL-2</td>
<td>44</td>
<td>0/2</td>
<td>5%</td>
<td>PRs: 11.5 (range 2.0 to 15.7+)</td>
<td>0</td>
<td>10.2</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>IL-2 + IFN</td>
<td>41</td>
<td>0/4</td>
<td>10%</td>
<td>p=0.30</td>
<td></td>
<td>9.7</td>
<td>p=NS</td>
<td></td>
</tr>
<tr>
<td>Rosenberg, 1993 (7) NCI</td>
<td>IL-2</td>
<td>22</td>
<td>0/6</td>
<td>27%</td>
<td>NR</td>
<td>0</td>
<td>2-yr: 15%</td>
<td>NR</td>
</tr>
<tr>
<td>IL-2 + LAK</td>
<td>27</td>
<td>3/3</td>
<td>22%</td>
<td></td>
<td>66+, 66+, 52+</td>
<td>2-yr: 32%</td>
<td>p=0.064</td>
<td></td>
</tr>
<tr>
<td>McCabe, 1991 (8) [abstract]</td>
<td>IL-2</td>
<td>45</td>
<td>2/5</td>
<td>16%</td>
<td>NR</td>
<td>6,12</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>IL-2 + LAK</td>
<td>49</td>
<td>3/3</td>
<td>12%</td>
<td></td>
<td></td>
<td>9, 24+, 29+</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td><strong>Trials of Low-dose IL-2</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agarwala, 2002 (9) IL-2</td>
<td>153</td>
<td>2/1</td>
<td>2%</td>
<td>NR</td>
<td>NR</td>
<td>8.2</td>
<td>p=0.038 (in favour of IL-2+HD, data NR)</td>
<td></td>
</tr>
<tr>
<td>IL-2 + HD</td>
<td>152</td>
<td>3/4</td>
<td>5%</td>
<td></td>
<td></td>
<td>9.1</td>
<td>p=0.125</td>
<td></td>
</tr>
<tr>
<td><strong>Trials of IL-2 Administered as a Continuous Intravenous Infusion</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Richards; 1990 (10) [abstract]</td>
<td>IL-2</td>
<td>33</td>
<td>0/3</td>
<td>9%</td>
<td>NR</td>
<td>NA</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>IL-2 + LAK</td>
<td>35</td>
<td>0/2</td>
<td>6%</td>
<td></td>
<td></td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
</tbody>
</table>

NOTES: CR = complete response; eval = evaluable; HD = histamine dihydrochloride; IFN = interferon; IL-2 = interleukin-2; LAK = lymphokine-activated killer cells; mos = months; NA = not applicable; NCI = National Cancer Institute; NR = not reported; NS = not significant; PR = partial response; pts = patients; ref = reference.
Outcome: toxicity

Grade 3/4 toxicity data for patients in the randomized trials of IL-2 can be found in Table 4. Richards et al (10) did not report any data on adverse effects for patients that received IL-2 alone or in combination with LAK. McCabe et al (8) did not report data on adverse effects except on the total number of toxic deaths.

For the trials of high-dose IL-2, both Sparano et al (6) and Rosenberg et al (7) reported high rates of the following types of grade 3/4 adverse effects: gastrointestinal, cardiovascular (especially hypotension), renal, neurologic, hematologic, and febrile neutropenia and sepsis. However, as Rosenberg et al pointed out, the majority of the toxic effects disappeared shortly after the administration of IL-2 was discontinued (7). There were a total of 13 toxic deaths out of a total of 347 patients in the three trials of high-dose IL-2 that reported on that outcome (6-8).

The low-dose IL-2 trial (9) reported much lower rates of grade 3/4 toxicities than the trials of high-dose IL-2 and the treatment was administered on an outpatient basis. The most frequent grade 3/4 toxicity was nausea in the IL-2 alone arm (8% of 153 patients), and febrile neutropenia in the IL-2 + HD arm (8% of 152 patients). The trial authors did not report data on the number of toxic deaths.
### Table 4. Randomized trials of IL-2: grade 3 or 4 toxicity.

<table>
<thead>
<tr>
<th>First author, year (Ref)</th>
<th>Arms</th>
<th># of pts</th>
<th>GI N/V (%)</th>
<th>Dr (%)</th>
<th>Hypotension (%)</th>
<th>Arr (%)</th>
<th>Isc / MI (%)</th>
<th>Renal - creatinine (%)</th>
<th>Hepatic</th>
<th>Neurologic</th>
<th>Hematologic</th>
<th>Febrile neut (%)</th>
<th>Sepsis (%)</th>
<th>Toxic deaths (# of pts)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Trials of High-dose IL-2</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sparano, 1993 (6)</td>
<td>IL-2</td>
<td>44</td>
<td>16</td>
<td>25</td>
<td>49</td>
<td>NR</td>
<td>9</td>
<td>41</td>
<td>18</td>
<td>11</td>
<td>27</td>
<td>2</td>
<td>NR</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>IL-2 + IFN</td>
<td>41</td>
<td>20</td>
<td>17</td>
<td>51</td>
<td>NR</td>
<td>0</td>
<td>39</td>
<td>29</td>
<td>0</td>
<td>29</td>
<td>0</td>
<td>NR</td>
<td>29</td>
</tr>
<tr>
<td>Rosenberg, 1993 (7)</td>
<td>IL-2</td>
<td>125a</td>
<td>76</td>
<td>66</td>
<td>61</td>
<td>7</td>
<td>1</td>
<td>80b</td>
<td>NR</td>
<td>88</td>
<td>26/13</td>
<td>c 4</td>
<td>42</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td>IL-2 + LAK</td>
<td>137a</td>
<td>75</td>
<td>69</td>
<td>74</td>
<td>9</td>
<td>2</td>
<td>87b</td>
<td>NR</td>
<td>90</td>
<td>25/15</td>
<td>c 4</td>
<td>71</td>
<td>NR</td>
</tr>
<tr>
<td>McCabe, 1991 (8)</td>
<td>IL-2</td>
<td>46</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td>IL-2 + LAK</td>
<td>52</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td><strong>Trials of Low-dose IL-2</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agarwala, 2002 (9)</td>
<td>IL-2</td>
<td>153</td>
<td>8/5</td>
<td>3</td>
<td>1</td>
<td>0d</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3/3</td>
<td>4</td>
<td>4e</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td>IL-2 + HD</td>
<td>152</td>
<td>7/6</td>
<td>1</td>
<td>1</td>
<td>1d</td>
<td>&lt;1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>2/2</td>
<td>0</td>
<td>2e</td>
<td>NR</td>
</tr>
<tr>
<td><strong>Trials of IL-2 Administered as a Continuous Intravenous Infusion</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Richards, 1990 (10) [abstract]</td>
<td>IL-2</td>
<td>33</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td>IL-2 + LAK</td>
<td>35</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
</tbody>
</table>

Notes: Alk Phos = alkaline phosphatase; Arr = arrhythmia; Bili = bilirubin; Dis = disorientation/confusion/dizziness; Dr = diarrhea; GI = gastrointestinal; HD = histamine dihydrochloride; IFN = interferon; IL-2 = interleukin-2; Isc = ischemia; LAK = lymphokine-activated killer cells; MI = myocardial infarction; N/V = nausea / vomiting; Neut = neutropenia; NR = not reported; pt(s) = patient(s); ref = reference; Som = somnolence; Thromb = thrombocytopenia; WBC = white blood cells.

a Number of cycles given to 85 and 79 patients in the IL-2 and IL-2 + LAK arms, respectively.
b Creatinine >2.1 mg/dL.
c Authors did not report toxicity grade for disorientation or somnolence.
d Tachycardia.
e Grade 3 or 4 anemia reported; unknown whether patients had transfusions.
Quality of life

Quality of life was examined only for patients in the randomized trial of low-dose IL-2 with or without HD reported by Agarwala et al (9). Data on QOL were collected and reported by Beusterien et al (24) in conjunction with that randomized trial. Quality of life data were collected prior to initiation of IL-2 therapy (baseline) and after every six-week cycle. The QOL survey included the Quality of Well Being-Self Administered (QWB-SA) questionnaire, an Overall State of Health item, and a General Health Perception item. The Overall State of Health item asked patients to rate their health over the preceding three day period on a scale from zero (least desirable state of health) to 100 (perfect health), and the General Health Perception item asked patients to rate their health on a scale from one (excellent) to five (poor). No significant differences were reported between the single-agent IL-2 arm and the combination treatment for the Overall State of Health or General Health Perception items.

The QWB-SA questionnaire included data for the following: symptom/complex, mobility, physical activity, and self-care - usual activity. Scores on the QWB-SA ranged from 0.0 (death) to 1.0 (optimum functioning without symptoms). Scores were calculated based on whether symptoms or problems were present one, two, and/or three days before filling out the questionnaire. Patients that died prior to completion of all cycles of therapy were assigned a QWB-SA score of 0.0 for all remaining treatment cycles. From a total of 305 randomized patients, 301 (98.7%) completed at least one QWB-SA questionnaire (IL-2 alone arm, 151 patients; IL-2 + HD, 150 patients). The IL-2 alone arm and the IL-2 + HD arm were similar in terms of missing data (34.9% and 33.4% missing questionnaires, respectively; p=0.419). The mean baseline QWB-SA score was 0.60 for both groups. The change in QWB-SA scores over time slightly favoured the IL-2 + HD group compared to the IL-2 alone group, however the difference was not statistically significant (p=0.511). Median quality-adjusted survival was longer in the IL-2 + HD arm compared to the IL-2 alone arm (105.6 days versus 74.3 days, respectively; p=0.007).

The QWB-SA data were also provided for a subgroup of patients that had liver metastases. Liver metastases were present prior to initiation of therapy in 73 of the 151 patients (48.3%) that completed at least one QWB-SA questionnaire in the IL-2 alone arm and in 53 of the 150 patients (35.3%) in the IL-2 + HD arm. The change in QWB-SA scores over time significantly favoured the IL-2 + HD arm compared to the IL-2 alone arm (p=0.018). Statistically significant differences in QWB-SA scores favouring the IL-2 + HD arm were present after cycle 2 (p=0.011), cycle 3 (p=0.002), cycle 4 (p=0.044), and cycle 5 (p=0.033), with differences in scores ranging from 0.11 to 0.16. Median quality-adjusted survival was longer in the IL-2 + HD arm compared to the IL-2 alone arm (113.0 days versus 62.8 days, respectively; p=0.011).

Phase II Trials

Overview

Twelve single-arm phase II trials were identified that examined the use of single-agent IL-2 and were included to obtain further evidence of objective tumour response, complete response, and durability of complete response as well as further information on toxicity and toxicity outcomes. Eight of those phase II trials administered high-dose IL-2 (11-19), and the remaining four trials administered IL-2 as a continuous intravenous infusion (20-23). The specific regimens for each trial are shown in Table 5.
Table 5. Single-arm phase II trials of IL-2: regimens.

<table>
<thead>
<tr>
<th>First author, year (ref)</th>
<th># pts (enrolled / evaluable)</th>
<th>IL-2 Regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Trials of High-dose IL-2</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agarwala, 2005 (11) [abstract]</td>
<td>26/26</td>
<td>600,000 IU/kg/dose (max 14 doses/cycle)</td>
</tr>
<tr>
<td>Pappo, 2001 (12)</td>
<td>21/21</td>
<td>720,000 IU/kg iv (15 min) q8hr for up to 5d (max 14 doses)</td>
</tr>
<tr>
<td>Atkins, 1999, 2000 (13,14)</td>
<td>270/270</td>
<td>600,000 or 720,000 IU/kg iv (15 min) q8hr for up to 5d (max 14 doses)</td>
</tr>
<tr>
<td>Rosenberg, 1998 (15)</td>
<td>182/182</td>
<td>720,000 IU/kg iv (15 min) q8hr for up to 5d (max 15 doses)</td>
</tr>
<tr>
<td>Whitehead, 1991 (16)</td>
<td>46/42</td>
<td>60 MIU/m²/d iv (15min) Mon, Wed, Fri</td>
</tr>
<tr>
<td>Parkinson, 1990 (17)</td>
<td>47/46</td>
<td>100,000 IU/kg/d iv (15min) q8hr d1-5</td>
</tr>
<tr>
<td>Rosenberg, 1989 (18)</td>
<td>60/42</td>
<td>100,000 IU/kg iv q8hr d1-5,14-18</td>
</tr>
<tr>
<td>Thatcher, 1989 (19)</td>
<td>16/16</td>
<td>11 MIU/m²/d is (1hr) d1, iv (1hr) d1 (4hr after is-dose), d3,5,7</td>
</tr>
</tbody>
</table>

**Trials of IL-2 Administered by Continuous Intravenous Infusion**

<table>
<thead>
<tr>
<th>First author, year (ref)</th>
<th># pts (enrolled / evaluable)</th>
<th>IL-2 Regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Legha, 1996 (20)</td>
<td>33/31</td>
<td>12 MIU/m² civ d1-4 (96 hrs) for 4 weeks</td>
</tr>
<tr>
<td>Vlasveld, 1994 (21)</td>
<td>15/15</td>
<td>1.8 MIU/m² civ (24 hrs) for 3 weeks</td>
</tr>
<tr>
<td>Dorval, 1992 (22)</td>
<td>24/24</td>
<td>20 MIU/m² civ d1-5,15-18,29-31</td>
</tr>
<tr>
<td>Paciucci, 1992 (23) Study 2</td>
<td>12/12</td>
<td>3.4 MIU/m² civ d1-6</td>
</tr>
</tbody>
</table>

Notes: # = number; civ = continuous intravenous infusion; d = day; hr = hour; IL-2 = interleukin-2; IU = International Units; iv = intravenous; is = intrasplenically; MIU = Million International Units; min = maximum; min = minutes; pts = patients; q = every; NCI = National Cancer Institute; ref = reference; SWOG = Southwest Oncology Group.

* Includes other cancer types; information in tables is for melanoma only.

* Reports on a subgroup of patients also included in the Atkins trial (13,14). Dose indicated in this trial differs from the dose indicated in the Atkins trial.

* The initial dose was decreased to 36 MIU/m²/d after 16 patients were treated because of toxic effects.

* Nine patients treated at the University of Maryland Cancer Centre might have received 15 doses of IL-2 per course. For all other patients, the maximum was 14 doses.

* Only the results of the phase II study are presented.

The characteristics of patients included in the non-comparative phase II trials of single-agent IL-2 are shown in Table 6. All of those trials reported patient PS, except for the trial reported by Pappo et al (12). Six trials used the ECOG PS scale (13,15,17,18,20,22), one trial, each, used the Southwest Oncology Group (SWOG) scale (16), Karnofsky scale (19), or Cancer and Leukemia Group B (CALGB) scale (23), and two trials did not report the scale used (11,21). All patients were reported as PS 0-2 (scale: ECOG, SWOG, CALGB, or not reported), except for patients in the trials by Rosenberg et al (18) who were reported as ECOG PS 0-3 and in the trial by Thatcher et al (19) who were reported as Karnofsky PS $\geq$50. Nine trials reported on prior treatment (11-17,19-21). Only one of those trials excluded patients that had received prior treatment (16). The remaining eight trials reported that patients had received prior chemotherapy, hormonal therapy, immunotherapy, limb perfusion, radiation therapy, surgery, or various combinations of those modalities. The percentages of patients that received prior treatment ranged from 1% of 182 patients that received hormonal therapy (15) to 100% of 26 patients that received biochemotherapy (11).

Nine trials reported the sites of metastases in patients receiving single-agent IL-2 (12-16,19-23). Sites of metastatic disease included the lungs, peritoneum, liver, lymph nodes, soft tissue, adrenal gland, bone, breasts, or gastrointestinal tract. None of the trials reported on lactate dehydrogenase. Six trials of high-dose single-agent IL-2 reported that patients were treated in an in-patient setting (11,12,15-17,19). One of the trials that administered single-agent IL-2 as a continuous intravenous infusion treated patients on an in-patient basis.
(20), one trial treated patients on an outpatient basis (21), and the two remaining trials did not report on treatment setting (22,23).

Table 6. Single-arm phase II trials of IL-2: patient characteristics.

<table>
<thead>
<tr>
<th>First author, year (ref)</th>
<th># of eval pts</th>
<th>Performance Status (% of pts)</th>
<th>Median Age (yrs)</th>
<th>Prior treatment specifics (% of pts)</th>
<th>Sites of metastases (% of pts)</th>
<th>Inpatient / Outpatient</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Trials of High-dose IL-2</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agarwala, 2005 (11) [abstract]</td>
<td>26</td>
<td>0-1, 100%</td>
<td>44</td>
<td>bioCT, 100%</td>
<td>NR</td>
<td>Inpatient</td>
</tr>
<tr>
<td>Pappo, 2001 (12)</td>
<td>21</td>
<td>NR</td>
<td>46</td>
<td>CT, RT, or IMT, 91%</td>
<td>Dermal/sub-dermal, 52%; lung, 52%; peritoneal, 28%; liver, 19%</td>
<td>Inpatient</td>
</tr>
<tr>
<td>Atkins, 1999, 2000 (13,14)</td>
<td>270</td>
<td>ECOG 0, 71% ECOG 1, 27% ECOG 2, 2%</td>
<td>42</td>
<td>CT, 14% IMT, 19% HT, 1% CM, 12%</td>
<td>Visceral, 69% Non-visceral, 31%</td>
<td>NR</td>
</tr>
<tr>
<td>Rosenberg, 1998 (15) NCI</td>
<td>182</td>
<td>ECOG 0, 81% ECOG 1, 16% ECOG 2, 3%</td>
<td>NR</td>
<td>Prior IL-2 therapy excluded. None, 1%; Sx, 97%; CT, 26%; RT, 16%; HT 1%; any 2 or more, 53%; any 3 or more, 20%</td>
<td>lung, lymph nodes, liver, intraperitoneal, (percentages not available)</td>
<td>Inpatient</td>
</tr>
<tr>
<td>Whitehead, 1991 (16) SWOG</td>
<td>42</td>
<td>SWOG 0, 60% SWOG 1, 40%</td>
<td>51</td>
<td>No prior treatment allowed</td>
<td>Non-visceral, 17% Visceral, 83%</td>
<td>Inpatient for first week of treatment</td>
</tr>
<tr>
<td>Parkinson, 1990 (17)</td>
<td>46</td>
<td>ECOG 0, 57% ECOG 1, 43%</td>
<td>Range 20-71</td>
<td>IMT, 17% CT, 17% RT, 13%</td>
<td>NR</td>
<td>Inpatient</td>
</tr>
<tr>
<td>Rosenberg, 1989 (18)</td>
<td>42</td>
<td>ECOG 0-3</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Thatcher, 1989 (19)</td>
<td>16</td>
<td>Karnofsky score ≥50</td>
<td>Range 30-69</td>
<td>CT, RT (%NR)</td>
<td>Visceral, 88% Non-visceral, 12%</td>
<td>Inpatient</td>
</tr>
<tr>
<td><strong>Trials of IL-2 Administered as a Continuous Intravenous Infusion</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Legha, 1996 (20)</td>
<td>31</td>
<td>ECOG 0, 70% ECOG 1, 30%</td>
<td>44</td>
<td>Prior IL-2 therapy excluded. None, 3%; CT, 97%; HT, 18%; IMT, 50%; RT, 21%</td>
<td>soft tissue only, 33% lung +/- soft tissue, 21% visceral, 46%</td>
<td>Inpatient</td>
</tr>
<tr>
<td>Vlasveld, 1994 (21)</td>
<td>15</td>
<td>0, 93% 1, 7%</td>
<td>51</td>
<td>Sx, 100% RT, 27% limb perfusion, 20%</td>
<td>skin, 73% lung, 20% liver, 13% lymph nodes, 7%</td>
<td>Outpatient</td>
</tr>
<tr>
<td>Dorval, 1992 (22)</td>
<td>24</td>
<td>ECOG 0, 71% ECOG 1, 29%</td>
<td>Range 19-62</td>
<td>NR</td>
<td>liver, 13%; adrenal gland, 8%; lymph nodes, 54%; cutaneous, 67%; subcutaneous, 8%; bone, 4%; lung, 17%; peritoneal carcinomatosis, 4%; breast, 4%, not specified, 4%</td>
<td>NR</td>
</tr>
<tr>
<td>Paciucci, 1992 (23) Study 2</td>
<td>12</td>
<td>CALGB 0-2</td>
<td>50</td>
<td>NR</td>
<td>lymph nodes, lung, liver, subcutaneous, skin, bone, gastrointestinal (% NR)</td>
<td>NR</td>
</tr>
</tbody>
</table>

Notes: bioCT = biochemotherapy; CALGB = Cancer and Leukemia Group B; CM = combination therapy; CT = chemotherapy; ECOG = Eastern Cooperative Oncology Group; HT = hormonal therapy; IL-2 = Interleukin-2; IMT = immunotherapy; NCI = National Cancer Institute; NR = not reported; pts = patients; ref = reference; RT = radiation therapy; SWOG = Southwest Oncology Group; Sx = surgery.

* includes 270 patients treated on eight phase II trials, including Parkinson (17) and McCabe (8).
**Outcome: response**

Tumour response data that was reported for patients in the non-comparative phase II trials of single-agent IL-2 can be found in Table 7. Atkins et al (13,14) combined and re-analyzed the results of eight separate clinical trials conducted between 1985 and 1993 that included 270 assessable patients. The objective response rate was 16% with a median time-to-progression of 13.1 months. Partial responses were observed on 10% of patients and complete responses were evident in 6%. Updated results published by Atkins et al in 2000 (14), reported a long-term duration of complete response of 59 months however, the median duration of complete responses had not yet been reached in this patient population. Similarly, Rosenberg et al (15) reported a trial on 182 patients, who demonstrated an objective response rate of 15% and a median duration of objective response of 16 months. The complete response rate was 7% with a median duration of complete response that had not yet been reached at a minimum follow-up of 70 months.

Objective response rates for the other six trials of high-dose single-agent IL-2 ranged from 10%-33% (11,12,16-19). Median duration of objective response was reported only by Parkinson et al (17) and Thatcher et al (19) as 8 months and 3.5 months, respectively. The complete response rate for the other six trials of high-dose single-agent IL-2 ranged from 0-15% (11,12,16-19). Duration of complete response was reported as ranging from four months to 148+ months in those trials.

All four complete responders reported by Agarwala et al had metastases to skin, subcutaneous tissue, and/or to distant lymph nodes (11). The single complete responder reported by Pappo et al had subcutaneous and lymphatic tissue metastases (12). Thirteen of 17 complete responders reported by Atkins et al had metastases involving the skin, lymph nodes, and/or the lungs (13,14). Eight of 12 complete responders reported by Rosenberg et al had lymphatic, lung, cutaneous and/or subcutaneous tissue metastases (15). Time to response was reported in only two trials, with Whitehead et al (16) reporting that four partial responses occurred between days 17 and 75, and Parkinson et al (17) reporting that all 10 objective responses occurred within 12 weeks of the first treatment. Median time to progression was 13.1 months in the trial reported by Atkins et al (13,14). None of the other trials of high-dose single-agent IL-2 reported on time to progression.

Objective response rates ranged from 0-58% in the four trials of IL-2 administered as a continuous infusion (20-23). The median duration of objective response was reported in two trials as 1.7 months and six months (20,22). The complete response rate ranged from 0-17% in all four trials. Duration of complete response was 18 months for the one patient with a complete response in the trial reported by Legha et al (20). Median time to progression was not reported in any of the three trials that reported patients that had an objective response.

**Outcome: overall survival**

Survival data for patients in the phase II trials of single-agent IL-2 can be found in Table 7. Median overall survival ranged from 9.8 months to 12.0 months in the three trials of high-dose IL-2 that reported on that outcome (11,13,14,16). Legha et al (20) reported a median overall survival of 9.7 months for 31 patients that received IL-2 administered as a continuous infusion. None of the other trials reported on overall survival.
Table 7. Single-arm phase II trials of IL-2: tumour response and overall survival.

<table>
<thead>
<tr>
<th>First author, year (ref)</th>
<th># of eval pts</th>
<th>CR/PR (# of pts)</th>
<th>Objective response rate (CR + PR)</th>
<th>Time to response</th>
<th>Median duration of response (CR + PR) (months)</th>
<th>Duration of CR (months)</th>
<th>Median survival (months)</th>
<th>Median time to progression (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Trials of High-dose IL-2</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Agarwala, 2005 (11) [abstract]</td>
<td>26</td>
<td>4/1</td>
<td>19%</td>
<td>NR</td>
<td>4,4,5,12+</td>
<td>9.8</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Pappo, 2001 (12)</td>
<td>21</td>
<td>1/6</td>
<td>33%</td>
<td>NR</td>
<td>NR</td>
<td>17</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Atkins, 1999, 2000 (13,14)</td>
<td>270a</td>
<td>17/26</td>
<td>16%</td>
<td>NR</td>
<td>8.9 PR: 5.9</td>
<td>Median: not reached (range 1.5- &gt;122)</td>
<td>12.0</td>
<td>13.1</td>
</tr>
<tr>
<td>Rosenberg, 1998 (15) NCIb</td>
<td>182</td>
<td>12/15</td>
<td>15%</td>
<td>NR</td>
<td>16 PR: 7</td>
<td>12, 16, 70+, 71+, 80+, 84+, 91+, 93+, 95+, 96+, 148+ (at median follow-up of 85.2 months)</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Whitehead, 1991 (16) SWOG</td>
<td>42</td>
<td>0/4</td>
<td>10% (95% CI, 3-23%)</td>
<td>Responses occurred on d17, 25, 49, 75</td>
<td>NR</td>
<td>NA</td>
<td>9.9</td>
<td>NR</td>
</tr>
<tr>
<td>Parkinson, 1990 (17)</td>
<td>46</td>
<td>2/8</td>
<td>22%</td>
<td>within 12w</td>
<td>9</td>
<td>14,20+</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Rosenberg, 1989 (18)</td>
<td>42</td>
<td>0/10</td>
<td>24%</td>
<td>NR</td>
<td>NR (range 2-41+)</td>
<td>NA</td>
<td>NA</td>
<td>NR</td>
</tr>
<tr>
<td>Thatcher, 1989 (19)</td>
<td>16</td>
<td>0/2</td>
<td>13%</td>
<td>NR</td>
<td>3.5 (range 3-4)</td>
<td>NA</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td><strong>Trials of IL-2 Administered as a Continuous Intravenous Infusion</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Legha, 1996 (20)</td>
<td>31</td>
<td>1/6</td>
<td>22% (95% CI, 10% to 41%)</td>
<td>NR</td>
<td>6 (range 4-18)</td>
<td>18</td>
<td>9.7 (range 1-56+)</td>
<td>NR</td>
</tr>
<tr>
<td>Vlasveld, 1994 (21)</td>
<td>15</td>
<td>0/0</td>
<td>0%</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Dorval, 1992 (22)</td>
<td>24</td>
<td>0/8</td>
<td>33%</td>
<td>NR</td>
<td>1.7 (range 6w to 5 months)</td>
<td>NA</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Paciucci, 1992 Study 2 (23)</td>
<td>12</td>
<td>2/5</td>
<td>58%</td>
<td>NR</td>
<td>4 months across all 3 studies</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
</tbody>
</table>

Notes: # = number; CI = confidence interval; CR = complete response; d = day; Eval = evaluable; IL-2 = interleukin-2; NA = not applicable; NCI = National Cancer Institute; NR = not reported; PR = partial response; pt(s) = patient(s); ref = reference; SWOG = Southwest Oncology Group; w = weeks.

a Includes 270 patients treated on eight phase II trials, including Parkinson (17) and McCabe (8).

b The following parameters were identified as significantly associated with complete response to treatment with IL-2 (numbers include 182 patients with metastatic melanoma and 227 patients with metastatic renal cancer): prior immunotherapy - 31/33 complete responders had no prior immunotherapy vs. 2/33 complete responders who did have prior immunotherapy (p=0.009); total IL-2 in first course: mean 11,171 IU/kg +/- 624 for complete responders vs. 9710 IU/kg +/- 183 for noncomplete responders (p=0.024); maximum lymphocytes (per mm³): 8048 +/- 900 for complete responders vs. 6514 +/- 668 for noncomplete responders (p=0.017).
Outcome: toxicity

Grade 3/4 toxicities for patients included in the single-arm phase II trials of single-agent IL-2 can be found in Table 8. The trials of high-dose IL-2 reported similar grade 3/4 toxicities to those reported in the randomized trials of high-dose IL-2. Both Pappo et al (12) and Rosenberg et al (15) reported that the toxic effects of treatment were similar to those reported in the past, and in the trials of high-dose IL-2 identified in this report. A number of studies has pointed out that adverse events resulting from IL-2 treatment are quite transient and tend to ceased once the treatment is discontinued (12, 15,16,18,19). Rosenberg et al concluded that over the years the safety of IL-2 administration has increased significantly. There were 16 toxic deaths among 948 patients in six phase II trials of high-dose IL-2 that reported on that outcome (12-18).

The single-arm phase II trials of IL-2 administered as a continuous infusion also reported similar rates of grade 3/4 toxicities as those reported in the high-dose IL-2 trials. Vlasveld et al (21) was the only identified trial that reported that no patients experienced grade 3/4 hypotension. However, the trial authors reported that 87% of patients experienced fatigue; data for other toxicities were not reported. Paciucci et al (23) reported that toxicities were substantial however the authors did not provide further details. Legha et al (20) reported only one toxic death among 33 patients. None of the other phase II continuous infusion IL-2 trials reported on the number of toxic deaths.

Quality of life

None of the identified non-comparative phase II trials of single-agent IL-2 included measures of QOL.
Table 8. Single-arm phase II trials of IL-2: grade 3 or 4 toxicity.

<table>
<thead>
<tr>
<th>First author, year (Ref)</th>
<th># of pts</th>
<th>Gl</th>
<th>Cardiovascular</th>
<th>Renal - creatinine</th>
<th>Hepatic</th>
<th>Neurologic</th>
<th>Hematologic</th>
<th>Febrile neut (%)</th>
<th>Sepsis (%)</th>
<th>Toxic deaths (# of pts)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>N/V</td>
<td>Dr</td>
<td>Hypo</td>
<td>Arr</td>
<td>Isc / MI</td>
<td>Alk Phos</td>
<td>Bili</td>
<td>Dis / Som</td>
<td>Coma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(%)</td>
<td>(%)</td>
<td>(%)</td>
<td>(%)</td>
<td>(%)</td>
<td>(%)</td>
<td>(%)</td>
<td>(%)</td>
<td>(%)</td>
</tr>
<tr>
<td>Agarwala, 2005 (11) [abstract]</td>
<td>26</td>
<td>NR</td>
<td>4</td>
<td>15</td>
<td>19&lt;sup&gt;a&lt;/sup&gt;</td>
<td>NR</td>
<td>NR</td>
<td>42</td>
<td>NR</td>
<td>NR&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Pappo, 2001 (12)</td>
<td>21</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Atkins, 1999 &amp; 2000 (13,14)</td>
<td>270</td>
<td>6/37</td>
<td>32</td>
<td>45</td>
<td>3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>3/1</td>
<td>1</td>
<td>2</td>
<td>9</td>
<td>13/3</td>
</tr>
<tr>
<td>Rosenberg, 1998 (15) NCI</td>
<td>409&lt;sup&gt;d&lt;/sup&gt;</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Whitehead, 1991 (16) SWOG</td>
<td>46</td>
<td>11</td>
<td>4</td>
<td>26</td>
<td>2</td>
<td>NR</td>
<td>7&lt;sup&gt;e&lt;/sup&gt;</td>
<td>11&lt;sup&gt;f&lt;/sup&gt;</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Parkinson, 1990 (17)</td>
<td>47</td>
<td>28</td>
<td>23</td>
<td>72</td>
<td>4</td>
<td>8</td>
<td>32&lt;sup&gt;h&lt;/sup&gt;</td>
<td>17</td>
<td>17</td>
<td>21/1</td>
</tr>
<tr>
<td>Rosenberg, 1989 (18)</td>
<td>236&lt;sup&gt;i&lt;/sup&gt;</td>
<td>69</td>
<td>61</td>
<td>50</td>
<td>6</td>
<td>4</td>
<td>74</td>
<td>NR</td>
<td>85</td>
<td>22/1</td>
</tr>
<tr>
<td>Thatcher, 1989 (19)</td>
<td>36&lt;sup&gt;g&lt;/sup&gt;</td>
<td>6</td>
<td>0</td>
<td>17</td>
<td>NR</td>
<td>NR</td>
<td>0</td>
<td>NR</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Legha, 1996 (20)</td>
<td>33</td>
<td>31</td>
<td>28</td>
<td>18</td>
<td>12</td>
<td>NR</td>
<td>12</td>
<td>NR</td>
<td>33</td>
<td>0</td>
</tr>
<tr>
<td>Vlasveld, 1994 (21)</td>
<td>23&lt;sup&gt;d&lt;/sup&gt;</td>
<td>NR</td>
<td>NR</td>
<td>0</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Dorval, 1992 (22)</td>
<td>24</td>
<td>NR</td>
<td>NR</td>
<td>54</td>
<td>NR</td>
<td>4</td>
<td>13</td>
<td>NR</td>
<td>13</td>
<td>NR</td>
</tr>
<tr>
<td>Paciucci, 1992 (23) Study 2</td>
<td>12</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
</tbody>
</table>

Notes: # = number; Alk Phos = alkaline phosphatase; Arr = arrhythmia; Bili = bilirubin; CNS = central nervous system; Dis = disorientation/confusion/dizziness; Dr = diarrhea; Gl = gastrointestinal; IL-2 = interleukin-2; Isc = ischemia; Leuk = leukopenia; MI = myocardial infarction; NCI = National Cancer Institute; N/V = nausea / vomiting; N neut = neutropenia; NR = not reported; pts = patients; ref = reference; Som = somnolence; SWOG = Southwest Oncology Group; Thomb = thrombocytopenia; WBC = white blood cells.

<sup>a</sup>Tachycardia.
<sup>b</sup>2 of 26 patients with grade 3 neurological toxicity
<sup>c</sup>Unknown whether patients had transfusion.
<sup>d</sup>Not all patients had melanoma - adverse effects reported as a percentage of total patients in the study.
<sup>e</sup>“Renal - other” adverse effects.
<sup>f</sup>“Hepatic - enzyme” adverse effects.
<sup>g</sup>Unknown whether patients had transfusion.
<sup>h</sup>Unknown whether patients had transfusion.
<sup>i</sup>“Renal - other” adverse effects.
<sup>j</sup>“Renal - other” adverse effects.
<sup>k</sup>“Renal - other” adverse effects.
<sup>l</sup>“Renal - other” adverse effects.
<sup>m</sup>“Renal - other” adverse effects.
<sup>n</sup>“Renal - other” adverse effects.
<sup;o</sup>“Renal - other” adverse effects.
DISCUSSION

Metastatic melanoma is known to be one of the most resistant forms of cancer and as a result is a devastating illness lacking effective therapies. Currently DTIC and IL-2 are the only two agents approved in the United States as first-line therapy for stage IV melanoma. Both regimens have demonstrated an objective response rate well below 20%. DTIC, along with other conventional chemotherapy regimens, such as temozolomide or the Dartmouth regimen, demonstrate results similar to IL-2, producing infrequent complete responses and objective responses ranging from 6.8 to 18.5%. To date, no single drug, combination chemotherapy or biotherapy compound, has demonstrated an overall survival benefit in a randomized clinical trial. Given the limited effective treatments available, along with the dismal survival of patients with metastatic melanoma, treatment with IL-2 warrants a closer evaluation.

Our analysis of the available literature identified a systematic review and meta-analysis of high-dose IL-2 (5) which presented data comparable to the case record-based review published by Keilholz et al (25). Both of those reviews reported similar response rates; 14.3% and 14.9%, respectively when IL-2 was used as a single agent. The response rate in both reviews was defined as complete responses plus partial responses, where the complete responders were not separated out. This response rate is similar to what is seen with single agent chemotherapy. The median survival was 8.1 months and 7.5 months, respectively, which is consistent with the median survival for metastatic melanoma with best supportive care.

None of the identified studies assessed IL-2 versus DTIC or any other single agent chemotherapy. Interleukin-2 can be administered using several dosing regimens however; none of the studies directly compared the different dosing schedules. The authors of this report divided the trials according to dose: high dose IL-2 (100,000 to 720,000IU/kg intravenously over 15 minutes every 8 hours for a maximum of 14 doses), low-dose IL-2 (2 to 9MIU/m² subcutaneously) and IL-2 administered as a continuous infusion (1.8MIU/m²/d to 20MIU/m²/d continuous intravenous infusion).

The three randomized trials (6-8) of high-dose IL-2 reported varying objective response rates from 5% to 27% with complete response rates for IL-2 alone or in combination ranging from 0-11%. Although only the trial reported by McCabe et al (8) had two complete responses in patients receiving IL-2 alone and both responses were of short duration (6 and 12 months). None of these trials showed a statistically significant improvement in overall survival or progression free survival.

There were eight phase II trials assessing high dose IL-2. The results of eight separate clinical trials of 270 assessable patients, conducted between 1985 and 1993, were combined and re-analyzed by Atkins et al (13,14). The authors reported an objective response rate of 16% with a median duration of response of 8.9 months. The complete response rate was 6%, with the median duration of complete response not yet reached, and with a minimum follow-up of 59 months. The trial reported by Rosenberg et al (15) included 182 assessable patients and supported the findings by Atkins et al (13,14). The Rosenberg trial (15) reported a complete response rate of 7% with a median duration of complete response that had not been reached at a minimum follow-up of 70 months. The other six trials involved smaller numbers of patients with three of those trials having reported seven patients with complete responses, with durations ranging from 4 to more than 20 months (11,12,17). The majority of complete responses in those trials were seen in patients with skin, lymph node, or lung involvement.

A randomized trial reported by Agarwala et al (9) assessed the benefit of low dose IL-2 with and without histamine. The authors reported an improvement in survival for patients with liver metastases with the combination of IL-2 and histamine compared to IL-2 alone. Further trials to confirm these results are underway. This systematic review also located four
single-arm trials of continuous infusion IL-2 which reported objective response rates varying from 0% to 58% (20-23). Complete responses were reported in two trials with rates of 3.2% (20) and 16.7% (23). These inconsistent results may be partly explained by the small sample sizes and patient selection differences.

Based on the identified evidence, high dose IL-2 as a single-agent or in combination with other agents provides little benefit with no improvement in survival. However, this trend is similar to numerous chemotherapeutic and immunological drug combinations that have failed to demonstrate a significant benefit in overall survival. The objective response rate seen with high-dose IL-2 treatment is similar to that seen with conventional chemotherapy and interferon in metastatic melanoma. However, the duration of complete response seen in phase II trials is impressive. An update of 270 patients with 43 responders by Atkins et al (14) reported a median duration of complete response of more than 59 months. This suggests a trend towards observed heightened survival in those who respond.

The identified trials included a heterogeneous population of patients with regard to disease sites, bulk of disease, performance status and prior treatments. Several studies have investigated factors associated with response to high dose IL-2 (27,28). In a retrospective review of 374 patients by Phan et al (27) patients with only subcutaneous and/or cutaneous metastases had a significantly higher response rate than patients with other sites of metastases (53.6% versus 12.4%, p=0.000001). Other factors such as high lymphocyte count post therapy, and development of vitiligo were associated with antitumour response to IL-2 therapy (27). Keilholz et al (25) performed a univariate analysis of pre-treatment factors and reported that ECOG performance status, number of involved organs, site of metastases and serum LDH all predicted for survival (p=0.0001). Therefore, patients with a good performance status (ECOG 0 or 1), less than 3 organs involved, cutaneous, and/or subcutaneous metastases only, and a normal LDH would have the highest probability of responding and should be considered for IL-2 therapy. Prior exposure to interferon therapy also lowered the response rate when compared to interferon naïve patients, 21% versus 13% respectively, but this was not statistically significant (28). None of the identified trials were sufficiently powered to examine specific subsets of patients; however, when looking at the characteristics of the complete responders, all but 4 patients in the trials had skin, lymphatic, or lung metastases.

The objective response rate or complete response rate data from the trials of continuous infusion IL-2 were not consistent with the rates reported in the trials of high dose IL-2. High-dose IL-2 shows impressive durable complete responses that are consistent across studies. High-dose IL-2 would be the dose of choice. The majority of the trials of high-dose single-agent IL-2 for metastatic melanoma (6,11,13,14,16) used a dose of 600,000 IU/kg/dose and the United States Food and Drug Administration approved that same dose for the treatment of patients with metastatic melanoma. Guidelines for the safe administration of high-dose IL-2 published by the Surgery Branch, National Cancer Institute, National Institutes of Health recommend a dose and schedule of 600,000 IU/kg/dose intravenously over 15 minutes, every eight hours, to a maximum of 14 doses (29).

Patients receiving IL-2 treatment may experience gastrointestinal, cardiovascular, pulmonary, renal, hepatic, septic and neurologic toxicity. Most of the trials identified in this systematic review reported that the majority of these adverse events were readily resolved upon termination of treatment. In addition, when IL-2 is administrated in appropriately selected patients, in an expert setting, the incidence of toxic death is rare (1-6%). Improved initial screening practices, enhanced patient monitoring along with growing expertise has resulted in significant decreases in treatment-mortality over the years. Kammula et al (30) reviewed the safety of administration of high dose IL-2 in a consecutive series of 1241 cancer patients treated over a 12 year period (1985 -1997) at the NCI Surgery Branch. Interestingly,
the study reported significant decreases in grade 3-4 toxicities over the years and more importantly there were no treatment related deaths in the last 809 patients reviewed (30).

The National Cancer Institute guidelines for the safe administration of high-dose IL-2 (29) provide guidance for pre-therapy assessment and intervention, patient monitoring during therapy, intervention during therapy and post-therapy assessment and intervention. It should be emphasized that IL-2 should only be administered by experienced clinicians in a centre with appropriate training and experience. Safety has not been established in patients with unresected brain metastases, or cardiac, renal, pulmonary, or hepatic dysfunction. Such patients should not be treated with high-dose IL-2 as part of a standard protocol.

Quality of life has not been assessed in patients receiving high dose IL-2. However, one randomized trial of low-dose single-agent IL-2 compared to low-dose IL-2 plus HD reported that median quality-adjusted survival was significantly longer for patients receiving the combination treatment (24). For patients with liver metastases, those that received IL-2 + HD had significantly longer median quality-adjusted survival and significantly less decline in QOL (measured by the QWB-SA questionnaire) over time than patients that received single-agent IL-2.

In summary, metastatic melanoma has a dismal prognosis for which our standard of care is the palliation of symptoms. At first glance, trials of high-dose IL-2 reported objective response rates similar to conventional chemotherapy. Data from three randomized controlled trials has demonstrated that single-agent IL-2, when given in high doses, can elicit an objective response rate of 5% to 27% with complete responses in 0% to 4% of patients (6,7,8). Similarly several noncomparative phase II trials of high-dose single-agent IL-2 have reported objective response rates of 10% to 33% with complete responses ranging from 0% to 15% (11-19). Complete responders in phase II trials have also demonstrated impressive long-term responses that range from 1.5 to 148 months (median 70 months). Though it has substantial toxicity, new guidelines and experience have made treatment with IL-2 manageable. The adverse effects are self-limiting and disappear shortly after completion of therapy. Given the data, it is possible to select appropriate patients for high-dose IL-2 that would have the greatest probability of response.

The studies which address prognostic factors suggest that it would be optimal to use IL-2 as first line therapy when disease burden is at its lowest. In this select group of patients, this therapy may be of potential value and should be considered as an option. However, given that some aspects of high dose IL-2 therapy remain investigational, and that response rates are low, patients should also be considered for clinical trials. Large randomized studies comparing IL-2 to DTIC or other chemotherapy are unlikely to be conducted in the future, as IL-2 is widely used in the United States and is an approved therapy in both Canada and the U.S.

ONGOING TRIALS

The National Cancer Institute's clinical trials database on the Internet (http://www.cancer.gov/search/clinical_trials/) was searched for reports of new or ongoing trials of single-agent IL-2 in the treatment of patients with metastatic melanoma.

<table>
<thead>
<tr>
<th>Protocol ID</th>
<th>Title and details of trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCCGHS-NCI-T98-0085,</td>
<td>Phase III Randomized Study of High-Dose Interleukin-2 With or Without gp100 Antigen in</td>
</tr>
<tr>
<td>NCI-T98-0085</td>
<td>Outcomes: Response, toxicity, progression-free and disease-free survival, quality-of-life.</td>
</tr>
<tr>
<td></td>
<td>Date last modified: 11/5/2004. Access: March 12, 2005. Available at:</td>
</tr>
</tbody>
</table>
CONCLUSIONS
Data from randomized trials as well as data from single-arm phase II trials of single-agent IL-2 demonstrate that IL-2 given in high doses can elicit an objective response rate of 5% to 33%. The randomized trials demonstrate that in the 0% to 11% of patients, who are complete responders, there have been consistent observations of long-term responses that range from 6 to 66+ months. Therefore, offering high-dose IL-2 to a select group of patients with metastatic melanoma is reasonable. Patients that have a good performance status (ECOG 0 or 1) and a normal LDH level, as well as having less than 3 organs involved or cutaneous and/or subcutaneous metastases only may benefit from treatment with high-dose IL-2. This carefully selected group of patients should be considered for treatment with high-dose IL-2 as no other therapy for metastatic melanoma has shown consistent durable responses.

There are no RCTs that compare high-dose IL-2 with the current standard treatment for metastatic melanoma, DTIC. However, DTIC is used for palliation of symptoms and offers low response rates with no benefit in survival.

High-dose IL-2 should be administered at a dose and schedule of 600,000 IU/kg/dose intravenously over 15 minutes, every eight hours, for a maximum of 14 doses. This is the same dose that the majority of trials of high-dose single-agent IL-2 used as well as the same dose as recommended by the National Cancer Institute.

High-dose IL-2 is an extremely toxic therapy, and it should be delivered only in a tertiary care facility where patients will receive appropriate monitoring by staff trained in the provisions of this treatment. Toxicity is manageable with the use of available guidelines and trained staff.

CONFLICT OF INTEREST
Members of the Melanoma DSG disclosed information on potential conflicts of interest. No potential conflicts were declared.

JOURNAL REFERENCES

ACKNOWLEDGEMENTS
The Melanoma DSG would like to thank Dr. Teresa Petrella, Dr. Ian Quirt, Dr. Shail Verma, Ms. Manya Charette, Mr. Adam Haynes, and Ms. Bak for taking the lead in drafting and revising this systematic review.

For a complete list of the Melanoma DSG members please visit the CCO Web site at http://www.cancercare.on.ca/

Funding
The PEBC is supported by Cancer Care Ontario (CCO) and the Ontario Ministry of Health and Long-Term Care. All work produced by the PEBC is editorially independent from its funding agencies.
Copyright
This evidence-based series is copyrighted by Cancer Care Ontario; the series and the illustrations herein may not be reproduced without the express written permission of Cancer Care Ontario. Cancer Care Ontario reserves the right at any time, and at its sole discretion, to change or revoke this authorization.

Disclaimer
Care has been taken in the preparation of the information contained in this document. Nonetheless, any person seeking to apply or consult the evidence-based series is expected to use independent medical judgment in the context of individual clinical circumstances or seek out the supervision of a qualified clinician. Cancer Care Ontario makes no representation or guarantees of any kind whatsoever regarding their content or use or application and disclaims any responsibility for their application or use in any way.

Contact Information
For further information about this Evidence-based Series, please contact:
Dr. Ian Quirt, Co-Chair, Melanoma Disease Site Group, Princess Margaret Hospital, 610 University Avenue, Toronto ON, M5G 2M9; TEL 416-946-2249; FAX 416-946-6546
or
Dr. Shail Verma, Co-Chair, Melanoma Disease Site Group, Integrated Cancer Program at The Ottawa Hospital - General Campus, 503 Smyth Road, Ottawa, ON, K1H 1C4; TEL 613-737-7700; FAX 613-247-3511.

For information about the PEBC and the most current version of all reports, please visit the CCO Web site at http://www.cancercare.on.ca/ or contact the PEBC office at:
Phone: 905-527-4322 ext. 42822 Fax: 905-526-6775 E-mail: ccopgi@mcmaster.ca
REFERENCES

Evidence-based Series #8-5: Section 3

Single-Agent Interleukin-2 in the Treatment of Metastatic Melanoma: Guideline Development and External Review: Methods and Results

T. Petrella, I. Quirt, S. Verma, A. Haynes, M. Charette, K. Bak, and members of the Melanoma Disease Site Group

A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO)
Developed by the Melanoma Disease Site Group


Report Date: March 20, 2006

THE PROGRAM IN EVIDENCE-BASED CARE

The Program in Evidence-based Care (PEBC) is an initiative of the Ontario provincial cancer system, Cancer Care Ontario (CCO) (1). The PEBC mandate is to improve the lives of Ontarians affected by cancer, through the development, dissemination, implementation, and evaluation of evidence-based products designed to facilitate clinical, planning, and policy decisions about cancer care.

The PEBC supports a network of disease-specific panels, called Disease Site Groups (DSGs) and Guideline Development Groups (GDGs), mandated to develop the PEBC products. These panels are comprised of clinicians, methodologists, and community representatives from across the province.

The PEBC is well known for producing evidence-based practice guideline reports, using the methods of the Practice Guidelines Development Cycle (1,2). The PEBC reports consist of a comprehensive systematic review of the clinical evidence on a specific cancer care topic, an interpretation of and consensus agreement on that evidence by our DSGs and GDGs, the resulting clinical recommendations, and an external review by Ontario clinicians in the province for whom the topic is relevant. The PEBC has a formal standardized process to ensure the currency of each clinical practice guideline report, through the routine periodic review and evaluation of the scientific literature and, where appropriate, the integration of that literature with the original clinical practice guideline information.
The Evidence-based Series

Each Evidence-based Series is comprised of three sections.

- **Section 1: Clinical Practice Guideline.** This section contains the clinical recommendations derived from a systematic review of the clinical and scientific literature and its interpretation by the DSG or GDG involved and a formalized external review by Ontario practitioners.

- **Section 2: Systematic Review.** This section presents the comprehensive systematic review of the clinical and scientific research on the topic and the conclusions reached by the DSG or GDG.

- **Section 3: Guideline Development and External Review: Methods and Results.** This section summarizes the guideline development process and the results of the formal external review by Ontario practitioners of the clinical practice guideline and systematic review.

DEVELOPMENT OF THIS EVIDENCE-BASED SERIES

Development and Internal Review

This evidence-based series was developed by the Melanoma DSG of CCO’s PEBC. The series is a convenient and up-to-date source of the best available evidence on single-agent interleukin-2 (IL-2) for patients with metastatic melanoma, developed through systematic review, evidence synthesis, and input from practitioners in Ontario.

Disease Site Group Consensus Process

The guideline was circulated for review and discussion by the Melanoma DSG on June 21, 2005. Most of the members conceded that given the available data, it would be optimal to use IL-2 as first line therapy in a select group of patients when disease burden is at its lowest. However, it should be noted that one member of the Melanoma DSG was not comfortable with the recommendations set out in this document, stating that IL-2 “is and remains an investigational drug” and thus should not be used as standard therapy.

External Review by Ontario Clinicians

Following review and discussion of sections 1 and 2 of this evidence-based series, the Melanoma DSG circulated the clinical practice guideline and systematic review to clinicians in Ontario for review and feedback. Box 1 summarizes the clinical recommendations developed by the panel.

**BOX 1: RECOMMENDATIONS** (approved for external review July 8, 2005)

<table>
<thead>
<tr>
<th><strong>Target Population</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients should have a good performance status (Eastern Cooperative Oncology Group [ECOG] 0-1), and a normal lactate dehydrogenase (LDH) level.</td>
</tr>
<tr>
<td>Patients should have less than three organs involved or have cutaneous and/or subcutaneous metastases only.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Recommendations</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>There is no high quality randomized controlled trial evidence to support or refute the use of interleukin-2 (IL-2) for patients with metastatic melanoma, and there are no studies that compare IL-2 to the current standard of care, dacarbazine (DTIC), or to placebo.</td>
</tr>
<tr>
<td>After weighing and reviewing the evidence that does exist, the opinion of the Melanoma Disease Site Group is that high-dose IL-2 is a reasonable treatment option for a select group of patients with metastatic melanoma:</td>
</tr>
</tbody>
</table>
The recommended dose and schedule of high-dose IL-2 is 600,000 IU/kg/dose intravenously over 15 minutes, every eight hours, for a maximum of 14 doses. If high-dose IL-2 is delivered, the recommendation is that it be done in a tertiary care facility with staff trained in the provision of this treatment with appropriate monitoring. To facilitate patient treatment and develop expertise in this therapeutic modality, the recommendation is that high-dose IL-2 programs be established in one or two centres in Ontario.

**Methods**
Feedback was obtained through a mailed survey of 276 practitioners in Ontario (medical oncologists, radiation oncologists and surgeons). The survey consisted of items evaluating the methods, results, and interpretive summary used to inform the recommendations and whether the recommendations should be approved as a practice guideline. Written comments were invited. The survey was mailed out on July 8, 2005. Follow-up reminders were sent at two weeks (post card) and four weeks (complete package mailed again). The Melanoma DSG reviewed the results of the survey.

**Results**
Sixty-five responses were received out of the 176 surveys sent (37% response rate). Responses include returned completed surveys as well as phone, fax, and email responses. Of the practitioners who responded, 29 (45%) indicated that the report was relevant to their clinical practice, and they completed the survey. Key results of the practitioner feedback survey are summarized in Table 9.

**Table 9. Responses to eight items on the practitioner feedback survey.**

<table>
<thead>
<tr>
<th>Item</th>
<th>Number (%)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>The rationale for developing a guideline, as stated in the “Introduction” section of the draft report, is clear.</td>
<td>27 (93%)</td>
</tr>
<tr>
<td>There is a need for a guideline on this topic.</td>
<td>27 (93%)</td>
</tr>
<tr>
<td>The literature search is relevant and complete (i.e., no key trials were missed nor any included that should not have been).</td>
<td>21 (72%)</td>
</tr>
<tr>
<td>The results of the trials described in the draft report are interpreted according to my understanding of the data.</td>
<td>26 (90%)</td>
</tr>
<tr>
<td>The draft recommendations in the report are clear.</td>
<td>29 (100%)</td>
</tr>
<tr>
<td>I agree with the draft recommendations as stated.</td>
<td>26 (90%)</td>
</tr>
<tr>
<td>This report should be approved as a practice guideline.</td>
<td>24 (82%)</td>
</tr>
<tr>
<td>If this report were to become a practice guideline, how likely would you be to make use of it in your own practice?</td>
<td>21 (76%)</td>
</tr>
</tbody>
</table>

*For some items, percentages may not total 100 due to rounding error.
† 5 (17%) practitioners indicated NA= not applicable for item #18 and 3 (10%) practitioners indicated NA= not applicable for item #19.
Summary of Written Comments
Twenty-two respondents (76%) provided written comments. The main points contained in the written comments were:

1. Two practitioners felt that there is insufficient evidence to recommend the use of IL-2 over other less toxic drugs. One of the two practitioners stated that the evidence of benefit is overstated and pointed out that in several studies the toxic death rate approximates complete response rates. Also pointing out that the guideline does not indicate “how to select eligible patients or what evidence supports selection (ie. no prospective studies showing selected patients do better).” A third practitioner also agreed that only a limited group would benefit and that it would be difficult to determine those fit enough to withstand the treatment.

2. Six respondents provided favourable comments and supported the guideline recommendations. Two of the six practitioners felt that administering IL-2 in Ontario is a more economically feasible option than sending patients to the United States. One respondent felt it would be practical to treat complete responders, however the challenge in establishment wait lists for these patients and centres to treat them in along with other associated financial costs will limit the application of these guidelines. It was also suggested that issues such as the cost of medicine, hospital visits and treatment of complications should be addressed.

3. Nine practitioners stated that they do not treat melanoma and/or that the guideline does not apply to them.

4. Six practitioners provided suggestions for future topics.

Modifications/Actions
The Melanoma DSG discussed the comments resulting from practitioner feedback and produced the following responses:

1. The DSG acknowledges that currently there is a lack of high quality evidence suggesting a clear survival benefit for IL-2 therapy. However, given the dismal survival of patients with metastatic melanoma and the fact that no other therapy offers the possibility for a durable complete remission the group believes that it is reasonable to recommend the use of high dose IL-2 to a select group of patients. The specific patient eligibility for this treatment is defined in Section 1 (page 2), Section 2 (pages 18 and 20), Section 3 (page 2) of the document. The group also agrees that high-dose IL-2 therapy presents considerable grade 3/4 toxicity; however; these adverse effects have become increasingly manageable. Delivering the treatment by adequately trained professionals in a designated tertiary care facility as well as following the National Cancer Institute’s guidelines for safe administration will insure safety and proper patient monitoring. The DSG has decided not to make any changes to the guideline.

2. The Melanoma group agrees that administering IL-2 therapy in Ontario, rather than referring patients for this treatment to the United States, is a more economically feasible option. Creating high-dose IL-2 programs in one or two centres in Ontario will not only facilitate patient treatment but also develop expertise in this therapeutic modality. The group recognizes the importance of financial concerns brought up by some of the respondents; however, the DSG’s main obligation is to establish clinical effect and determine best evidence-based practice, thus, assessing issues of cost and/or economic benefit is outside of the purview of this document.
**Report Approval Panel**

The final Evidence-based Series report was reviewed and approved by the PEBC Report Approval Panel in May, 2006. The Panel consists of two members including an oncologist, with expertise in clinical and methodology issues. Key issues raised by the Panel included:

1. The RCTs address all of the relevant outcomes although the data from the phase II trials are more favourable. Inclusion of the phase II data may be viewed as biased; therefore, clearer justification for the inclusion of the phase II data should be provided.

2. Where data is summarized (e.g. in the Key Evidence section), the RCT data should be included along with the phase II data. For example, complete response rates with high-dose IL-2 range from 0%.

3. Further discussion of the trade-offs of the treatment would be useful. The treatment may offer the best palliation option; however, it can lead to a miserable death with adverse effects for a slim chance of survival with unknown QOL because there are no appropriate comparisons.

4. It appears that access to this treatment is a topical subject, although the background for this only becomes apparent in the Practitioner Feedback section. If access to therapy was a contributing factor that led to the DSG selecting this topic, it would be appropriate to state this in the Introduction section.

5. The recommendations are principally based on studies that provide a lower level of evidence and principally assess an outcome that does not usually drive policy decisions. The DSG has done a relatively good job of explaining how it concluded that a recommendation to support availability of this therapy was appropriate. However, given the relatively unusual nature of recommending a therapy based on such data, and given the toxicity of the agent that may require development of special sites of provincial expertise, I think the DSG needs to go further to address how the potential benefits of this therapy “outweigh” the limitations of the data. Specifically:
   i) context regarding the importance of response as an outcome measure would be helpful.
   ii) an indication of whether the prolonged periods of disease control seen in CR patients is unique, or whether this is seen in patients who respond to other therapies, would be helpful. There is a further risk of criticism that the DSG has compared overall responses to IL-2 with the historical results associated with other therapies, but is only providing the data for durable responses with IL-2.
   iii) the DSG also risks criticism for its last sentence in the Discussion (p 19) that suggests that IL-2 might be considered as first-line therapy. This consideration appears to be principally based on analyses of prognostic factors. The difficulty is that patients with earlier stages of disease will always do better than those with more advanced disease, regardless of the therapy provided. More background is required to support this supposition.

6. The DSG also should consider providing broader context of the Agarwala study. This RCT was the largest of those reported, and described differences in median time to disease progression (likely a more “policy-determining” outcome than response) and median quality-adjusted survival. While the potential limitations of these data can be appreciated, an explanation of the reasons for not using the results of this trial to form recommendations when trials that have more severe limitations have been used would be helpful.
**Modifications/Actions**

The Melanoma DSG discussed the comments resulting from the PEBC Report Approval Panel and produced the following responses and modifications:

1. The DSG felt that the inclusion of phase II data was necessary due to the limited availability of phase III data. In order to further justify the inclusion of phase II data a Qualifying Statement has been added to Section One of the document.
2. The Key Evidence section has been modified to reflect these suggestions.
3. The working group would like to point out that IL-2 is not a palliative treatment. IL-2 offers similar response rates to the current standard of care, DTIC, adverse events are manageable and reversible and death due to treatment in no longer common.
4. Access to therapy was not a contributing factor that lead to the DSG’s selection of this topic. The purpose of this document is to establish clinical effect and determine best evidence-based practice. However, the DSG would like to point out that access to treatment is addressed in the document (Discussion section).
5. The discussion section has been expanded to further address the benefits of IL-2 therapy and Qualifying Statements have been added to explain the DSG’s decision to recommend IL-2 as first line therapy.
6. The DSG decided not to use the results of the Agarwala trial to form its recommendations because the trial randomized its patients to treatment with low-dose IL-2. Low dose IL-2 had consistently lower overall response rates (2 to 5%) compared to high dose IL-2 and hence was not part of the recommendation.

**Policy Review**

A draft of this evidence series was submitted to the Drug Quality and Therapeutics Committee/Cancer Care Ontario (DQTC/CCO) Subcommittee in 2005.

**Funding**

The PEBC is supported by Cancer Care Ontario (CCO) and the Ontario Ministry of Health and Long-Term Care. All work produced by the PEBC is editorially independent from its funding agencies.

**Copyright**

This evidence-based series is copyrighted by Cancer Care Ontario; the series and the illustrations herein may not be reproduced without the express written permission of Cancer Care Ontario. Cancer Care Ontario reserves the right at any time, and at its sole discretion, to change or revoke this authorization.

**Disclaimer**

Care has been taken in the preparation of the information contained in this document. Nonetheless, any person seeking to apply or consult the evidence-based series is expected to use independent medical judgment in the context of individual clinical circumstances or seek out the supervision of a qualified clinician. Cancer Care Ontario makes no representation or guarantees of any kind whatsoever regarding their content or use or application and disclaims any responsibility for their application or use in any way.

**Contact Information**

For further information about this Evidence-based Series, please contact:
Dr. Ian Quirt, Co-Chair, Melanoma Disease Site Group, Princess Margaret Hospital, 610 University Avenue, Toronto ON, M5G 2M9; TEL 416-946-2249; FAX 416-946-6546

or
Dr. Shail Verma, Co-Chair, Melanoma Disease Site Group, Integrated Cancer Program at The Ottawa Hospital - General Campus, 503 Smyth Road, Ottawa, ON, K1H 1C4; TEL 613-737-7700; FAX 613-247-3511.

For information about the PEBC and the most current version of all reports, please visit the CCO Web site at http://www.cancercare.on.ca/ or contact the PEBC office at:
Phone: 905-527-4322 ext. 42822 Fax: 905 526-6775
REFERENCES


**EBS 8-5 Document Assessment and Review Tool.**

**DOCUMENT ASSESSMENT AND REVIEW TOOL**

<table>
<thead>
<tr>
<th>Number and title of document under review</th>
<th>EBS #8-5 Single-Agent Interleukin-2 In The Treatment Of Metastatic Melanoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of current version</td>
<td>March 20, 2006</td>
</tr>
<tr>
<td>Clinical reviewer</td>
<td>Dr. Teresa Petrella</td>
</tr>
<tr>
<td>Research coordinator</td>
<td>Rovena Tey</td>
</tr>
<tr>
<td>Date initiated</td>
<td>June 10, 2010</td>
</tr>
<tr>
<td>Date and final results / outcomes</td>
<td>August 4, 2010 (Endorsed)</td>
</tr>
</tbody>
</table>

**Instructions.** Beginning at question 1, below, answer the questions in sequential order, following the instructions in the black boxes as you go.

1. Is there still a need for a guideline covering one or more of the topics in this document as is? Answer Yes or No, and explain if necessary:
   - **YES**
     - This guideline is needed by the University Health Network (UHN) and Ministry of Health (MOH) to create an Ontario-based Interleukin-2 treatment program
   - If No, then the document should be ARCHIVED1 with no further action; go to 11. If Yes, then go to 2.

2. Are all the current recommendations based on the current questions definitive or sufficient, and have less than 5 years elapsed since the latest search? Answer Yes or No, and explain if necessary:
   - Definitive or Sufficient
     - **YES**
       - The current recommendations are probably definitive and sufficient, however, an updated literature search should still be conducted to see what new evidence might turn up
       - There may be new studies on molecular markers, which would be useful to answer Guideline Q2 about selecting patients for treatment.
     - If Yes, the document can be ENDORSED2 with no further action; go to 11. If No, go to 3.

3. Is there expected or known evidence that contradicts the current recommendations, such that they may cause harm or lead to unnecessary or improper treatment if followed? Answer Yes or No, and explain if necessary, providing references of known evidence:
   - **NO**
   - If Yes, the document should be taken off the website as soon as possible. A WARNING3 should be put in its place informing a user that the document is only available by email, with a brief explanation of the reasons. If No, go to 4.

4. Do current resources allow for an updated literature search to be conducted at this time? Answer Yes or No, and explain as necessary. Provide an expected date of completion of the updated search, if applicable:
   - **YES**
     - There is a designated research co-ordinator at the PEBC to carry out the literature search
     - Updated literature search to be completed by mid-July 2010
   - If No, a DEFERRAL4 should be placed on the document indicating it cannot be updated at this time, but will be reviewed again on a yearly basis. If Yes, go to 5.
5a. **Guideline Research Questions.** Please review the original guideline research questions below and if applicable, list any MINOR changes to the questions that now must be considered. If a question is no longer relevant, it can be deleted. The Document Assessment and Review process evaluates the guideline as is and CANNOT accommodate significant changes to the questions or the addition of new questions introducing new patient populations or new agents/interventions because if this what is required in order to make this guideline relevant, then a brand new document should be produced and this guideline as is should be ARCHIVED (i.e., go back to Q1 of this form and answer NO).

- No changes to the original questions

**Original Questions:**

1. What is the role of single-agent interleukin-2 (IL-2) in the treatment of adults with metastatic melanoma? Primary outcomes of interest include objective response rates, complete response rates, duration of response, toxicity, and quality of life. Secondary outcomes of interest include progression-free survival and overall survival.

2. If there is a role for single-agent IL-2, what is the appropriate patient population to be considered for treatment?

3. If there is a role for single-agent IL-2, what is the appropriate dose and schedule?

4. What are the toxicities associated with IL-2?

5b. **Inclusion and Exclusion criteria.** List below any changes to the selection criteria in the original version made necessary by new questions, changes to existing questions, or changes in available evidence (e.g., limit a search to randomized trials that originally included non-randomized evidence).

- No changes to the inclusion or exclusion criteria

- It is still important to include both RCTs and non-randomized phase II studies because it is still unlikely that there would be many randomized studies on this topic, especially to answer Guideline Q2 about patient populations

**Inclusion Criteria:**

The following types of articles were selected for inclusion in this systematic review of the evidence:

1. Full reports or abstracts of randomized controlled trials or randomized phase II trials in which one trial arm involved single-agent IL-2 for patients with metastatic melanoma.

2. Full reports or abstracts of single-arm phase II trials of single-agent IL-2 for patients with metastatic melanoma, which were included because insufficient evidence was available from randomized controlled trials.

3. Meta-analyses of randomized controlled trials, systematic reviews and evidence-based practice guidelines.

**Exclusion Criteria:**

1. Papers published in a language other than English were not considered due to limited resources for translation.

2. Phase I studies were not considered.

3. Reports that provided data for a sample of less than 10 patients with metastatic melanoma were excluded.

5c. Conduct an updated literature search based on that done for the current version and modified by 5a and 5b above. Report the results below.

**Full Selection Criteria:**

The following types of articles were selected for inclusion in this systematic review of the evidence:
1. Full reports or abstracts of randomized controlled trials or randomized phase II trials in which one trial arm involved single-agent IL-2 for patients with metastatic melanoma.

2. Full reports or abstracts of single-arm phase II trials of single-agent IL-2 for patients with metastatic melanoma, which were included because insufficient evidence was available from randomized controlled trials.

3. Meta-analyses of randomized controlled trials, systematic reviews and evidence-based practice guidelines.

Exclusion Criteria:
1. Papers published in a language other than English were not considered due to limited resources for translation.

2. Phase I studies were not considered.

3. Reports that provided data for a sample of less than 10 patients with metastatic melanoma were excluded.

Search Period:
- March 2006 to 18th June 2010 (Medline + Embase)
- 2006 to 2010 (ASCO Annual Meeting)

Brief Summary/Discussion of New Evidence:
Of 530 total hits from the Medline + Embase search and looking through 519 ASCO conference abstracts, 8 references representing 8 potentially new studies were found evaluating high-dose IL2 in metastatic melanoma, of which there was 1 RCT. 2 were full text publications and 6 were abstracts.

The **BOLD** text within the table (last 3 rows) represent evidence that might help answer research Q2 regarding the selection of patients to be considered for IL2 treatment.

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Study type</th>
<th>Population</th>
<th>Outcomes</th>
<th>Brief results</th>
<th>References</th>
</tr>
</thead>
</table>
| High-dose IL2 (720 000 IU/kg) vs. peptide vaccine + high-dose IL2 | Ph 3 RCT | Stg 4 metastatic or stg 3 locally advanced cutaneous melanoma | 1 = response & CR, PR, PFS, OS, toxicity | For IL2 vs. vaccine + IL2:  
- Response = 9.7% vs. 22% (P=0.02)  
- CR = 2.2% vs. 14% (P=0.003)  
- PR = grps did not differ  
- PFS = 1.6 mo vs. 2.9 mo (P=0.01)  
- Median OS = grps did not differ  
- The IL2 + vaccine grp had more cardiovascular arrhythmias | (Schwartzenthuber DJ et al. 2009) [abstract] |
| High-dose IL2 (600 000 to 720 000 U/kg/8h) | Ph 2 single-arm non-RCT | Stg 4 metastatic melanoma, previously treated with biochemotherapy (cisplatin, vinblastine, dacarbazine, IL2, IFNa-2b) | ORR, survival, PFS, toxicity | ORR = 19%  
- median survival time at 10 mo = 42 wks (CI 19 to 87)  
- median PFS at 10 mo = 10 wks (CI 8 to 16)  
- Grd 3/4 toxicity included hyperbilirubinemia, thrombocytopenia, oliguria | (Tarhini AA et al. 2007) |
| High-dose IL2 (600 000 to 720 000 U/kg/8h) | Single-arm study | Metastatic melanoma | OS, PFS, response | Median OS = 1.94 y  
Median PFS = 57 d  
Response = 30% | (Joseph RW et al. 2010) [abstract] |
| High-dose IL2 (600 000 IU/kg/8h) | Retrospective | Metastatic melanoma, previously treated with biochemotherapy (cisplatin, vinblastine, dacarbazine, INFa, IL2) | CR, PR, TTP, OS | CR = 5% (n=1)  
PR = 27%  
DoR range = 1 to 18 mo  
DFS = no survivors  
Median TTP at 36 mo = 2.5 mo  
Median OS at 36 mo = 9.5 mo | (Schmerling RA et al. 2006) [abstract] |
<table>
<thead>
<tr>
<th>Study Type</th>
<th>Design</th>
<th>Patient Population</th>
<th>Outcomes</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>High-dose IL2 (600,000 IU/kg)</td>
<td>Retrospective</td>
<td>Stg 4 metastatic melanoma</td>
<td>CR, PR, TTP, toxicity</td>
<td>CR = 6.7% (n=1) PR = 6.7% (n=1) TTP = 5.7 mo Grd 3/4 toxicity included hyperbilirubinemia, hypotension, peripheral edema</td>
</tr>
<tr>
<td>High-dose IL2</td>
<td>Single-arm study and retrospective clinical prediction study (no validation set)</td>
<td>Advanced melanoma</td>
<td>Response, CR, PR, OS, PFS, predictive gene expression signature to treatment response</td>
<td>Response = 33% CR = 8% PR = 25% Median OS = 24 mo Median PFS = 3.3 mo Tumours expressing immune genes were more likely to respond to treatment compared with tumours expressing melanocyte genes</td>
</tr>
<tr>
<td>High-dose IL2 (600,000 U/kg/8h)</td>
<td>Clinical prediction study (training and validation sets)</td>
<td>Mix of pts with metastatic melanoma (n=48) and renal cell carcinoma (n = 11)</td>
<td>CR, PR, toxicity, predictive biomarkers of treatment response</td>
<td>In pts with melanoma, 37% achieved a response (10% CR + 27% PR) There were no serious adverse events or treatment-related mortality High levels of serum VEGF and fibronectin correlated with lack of clinical response and decreased OS</td>
</tr>
<tr>
<td>High-dose IL2</td>
<td>Retrospective clinical prediction study</td>
<td>Metastatic melanoma</td>
<td>Predictive hemodynamic parameters to treatment response</td>
<td>Greater decrease in corrected mean BP at baseline, lower corrected mean BP during treatment, and decreases in corrected systolic and diastolic BP were associated with a response to treatment No correlation was found between heart rate or number of IL2 doses and treatment response</td>
</tr>
</tbody>
</table>

New References Identified (alphabetical order):


**Literature Search Strategy:**

**Medline**
1. meta-Analysis as topic/
2. meta analysis.pt.
3. (meta analy$ or metaanaly$).tw.
4. (systematic review$ or pooled analy$ or statistical pooling or mathematical pooling or statistical summar$ or mathematical summar$ or quantitative synthesis$ or quantitative overview$).tw.
5. (systematic adj (review$ or overview$)).tw.
6. (exp Review Literature as topic/ or review.pt. or exp review/) and systematic.tw.
7. or/1-6
8. (cochrane or embase or psychlit or psyclit or psycinfo or psychinfo or cinahl or cinhal or science citation index or scisearch or bids or sigle or cancerlit).ab.
9. (reference list$ or bibliograph$ or hand-search$ or relevant journals or manual search$).ab.
10. (selection criteria or data extraction or quality assessment or jadad scale or methodological quality).ab.
11. (study adj selection).ab.
12. 10 or 11
13. review.pt.
14. 12 and 13
15. exp randomized controlled trials as topic/ or exp clinical trials, phase III as topic/ or exp clinical trials, phase IV as topic/
16. (randomized controlled trial or clinical trial, phase III or clinical trial, phase IV).pt.
17. random allocation/ or double blind method/ or single blind method/
18. (random$ control$ trial? or rct or phase III or phase IV or phase 3 or phase 4).tw.
19. or/15-18
20. (phase II or phase 2).tw. or exp clinical trial/ or exp clinical trial as topic/
21. (clinical trial or clinical trial, phase II or controlled clinical trial).pt.
22. 20 or 21
23. (clinical$ adj trial$1).tw.
24. ((singl$ or doubl$ or treb$ or tripl$) adj (blind$3 or mask$3 or dummy)).tw.
25. placebos/
26. (placebo$ or random allocation or randomly allocated or allocated randomly).tw.
27. (allocated adj2 random).tw.
28. or/23-27
29. practice guidelines/
30. practice guideline?.tw.
31. practice guideline.pt.
32. or/29-31
33. 7 or 8 or 9 or 14 or 19 or 22 or 28 or 32
34. (comment or letter or editorial or note or erratum or short survey or news or newspaper article or patient education handout or case report or historical article).pt.
35. 33 not 34
36. limit 35 to english
37. limit 36 to human
38. exp melanoma/
39. melanoma.mp.
40. 38 or 39
41. interleukin-2/ or IL-2/
42. (interleukin 2 or interleukin-2 or IL-2 or IL 2).mp.
43. 41 or 42
44. 40 and 43
45. 37 and 44
46. (200603$ or 2007$ or 2008$ or 2009$ or 2010$).ed.
47. 45 and 46

**Embase**
1. exp meta analysis/ or exp systematic review/
2. (meta analy$ or metaanaly$).tw.
3. (systematic review$ or pooled analy$ or statistical pooling or mathematical pooling or statistical summar$ or mathematical summar$ or quantitative synthesis$ or quantitative overview$).tw.
4. (systematic adj (review$ or overview$)).tw.
5. exp review/ or review.pt.
6. (systematic or selection criteria or data extraction or quality assessment or jadad scale or methodological quality).ab.
7. (study adj selection).ab.
8. 5 and (6 or 7)
9. or 1-4, 8
10. (cochrane or embase or psychlit or psychinfo or psycinfo or cinahl or cinhal or science citation index or scisearch or bids or sigle or cancerlit).ab.
11. (reference list$ or bibliograph$ or hand-search$ or relevant journals or manual search$).ab.
12. exp randomized controlled trial/ or exp phase 3 clinical trial/ or exp phase 4 clinical trial/
13. randomization/ or single blind procedure/ or double blind procedure/
14. (random$ control$ trial? or rct or phase III or phase IV or phase 3 or phase 4).tw.
15. or/12-14
16. (phase II or phase 2).tw. or exp clinical trial/ or exp prospective study/ or exp controlled clinical trial/
17. (clinical adj trial$1).tw.
18. ((singl$ or doubl$ or treb$ or tripl$) adj (blind$3 or mask$3 or dummy)).tw.
19. placebo/
20. (placebo? or random allocation or randomly allocated or allocated randomly).tw.
22. or/17-21
23. practice guidelines/
24. practice guideline?.tw.
25. practice guideline.pt.
26. or/23-25
27. 9 or 10 or 11 or 15 or 16 or 22 or 26
28. (editorial or note or letter or erratum or short survey).pt. or abstract report/ or letter/ or case study/
29. 27 not 28
30. limit 29 to english
31. limit 30 to human
32. exp melanoma/
33. melanoma.mp.
34. 32 or 33
35. interleukin-2/ or IL-2/
36. (interleukin 2 or interleukin-2 or IL-2 or IL 2).mp.
37. 35 or 36
38. 34 and 37
39. 31 and 38
40. (200615$ or 2007$ or 2008$ or 2009$ or 2010$).ew.
41. 39 and 40

ASCO Annual Meeting - manually checked all abstracts from www.asco.org in the section: Melanoma/Skin Cancers (2006 to 2010)

Go to 6.

6. Is the volume and content of the new evidence so extensive such that a simple update will be difficult?
6. NO

If Yes, then the document should be ARCHIVED with no further action; go to 11. If No, go to 7.

7. On initial review, does the newly identified evidence support the existing recommendations? Do the current recommendations cover all relevant subjects addressed by the evidence, such that no new recommendations are necessary? Answer Yes or No, and explain if necessary:
7. YES
   • No new recommendations are needed as the studies addressing patient populations are retrospective or single arm studies and would require prospective validation in larger data sets prior to being incorporated into clinical practice
   • The rest of the data does not change our current recommendations
   • Therefore, Guideline 8-5 can be ENDORSED.

If Yes, the document can be ENDORSED. If No, go to 8.

8. Does any of the newly identified evidence, on initial review, contradict the current recommendations, such that the current recommendations may cause harm or lead to unnecessary or improper treatment if followed? Answer Yes or No, and explain if necessary, citing newly identified references:
8. Not applicable.

If Yes, a WARNING note will be placed on the web site. If No, go to 9.
9. Is there a good reason (e.g., new stronger evidence will be published soon, changes to current recommendations are trivial or address very limited situations) to postpone updating the guideline? Answer Yes or No, and explain if necessary:

<table>
<thead>
<tr>
<th>9. Not applicable.</th>
</tr>
</thead>
<tbody>
<tr>
<td>If Yes, the document update will be <strong>DEFERRED</strong>, indicating that the document can be used for decision making and the update will be deferred until the expected evidence becomes available. If No, go to 10.</td>
</tr>
</tbody>
</table>

10. An update should be initiated as soon as possible. List the expected date of completion of the update:

<table>
<thead>
<tr>
<th>10. Not applicable.</th>
</tr>
</thead>
<tbody>
<tr>
<td>An <strong>UPDATE</strong> will be posted on the website, indicating an update is in progress.</td>
</tr>
</tbody>
</table>

11. Circulate this form to the appropriate Disease Site Group for their approval. Once approved, a copy of this form should be placed behind the cover page of the current document on the website. Notify the original authors of the document about this review.

<table>
<thead>
<tr>
<th>DSG Approval Date:</th>
<th>August 4, 2010</th>
</tr>
</thead>
</table>
DOCUMENT ASSESSMENT & REVIEW 5-STEP FLOW CHART

**METHODS & RESULTS - page 16**

**STEPS**

1. **Initiation of the Document Assessment & Review process**
   - **Outcomes**
   - **Action**
   - RC emails DSG reviewer(s) the protocol
   - Discuss questions #1-5

2. **First teleconference to determine:**
   - the clinical relevance of the guideline,
   - if a new literature search is needed, and
   - if Yes, the search criteria.

   - **#1.** Is there still a **NEED** for a guideline covering one or more of the topics in this document?
   - Yes → **Endorse**
   - No → **Archive**

   - **#2.** Are all the current recommendations based on the current questions definitive* or sufficient§, and have less than 5 years elapsed since the latest search?
   - Yes to all → **Endorse**
   - No → **Warning**

   - **#3.** Is there expected or known evidence that contradicts the current recommendations, such that they may cause harm or lead to unnecessary or improper treatment if followed?
   - Yes → **Warning**
   - No → **Deferral**

   - **#4.** Do current resources allow for an updated literature search to be conducted at this time?
   - Yes → New search
   - No → Deferral

   - **#5.** List any new and relevant questions that have arisen since the last version of the document. List any changes to the original research questions that now must be considered. Determine the search criteria.

3. **A new literature search based on input from #5 will be conducted, and the result will be sent to the reviewers with a follow-up date**
FLOW CHART (cont.)

**STEPS**

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Archive</td>
<td>Review questions #6-9</td>
</tr>
<tr>
<td>Endorse</td>
<td>Please note: No teleconference needed, IF the reviewer(s) complete and return the form with answers &amp; explanations.</td>
</tr>
<tr>
<td>Deferral</td>
<td>Teleconference with the reviewer(s) to discuss the type of update, priority, and resources.</td>
</tr>
<tr>
<td>Update</td>
<td>RC emails draft for DSG approval</td>
</tr>
</tbody>
</table>

**STEP 4: Second teleconference to determine the ultimate status of the document**

**#6.** Are the volume and content of the newly identified evidence such that a new document is necessary to address the topic?

- Yes
  - Archive
- No
  - **#7.** Does the newly identified evidence support the existing recommendations? Do the current recommendations cover all relevant subjects addressed by the evidence, such that no new recommendations are necessary?

- Yes
  - Endorse
- No
  - **#8.** Does any of the newly identified evidence, on initial review, contradict the current recommendations, such that the current recommendations may cause harm or lead to unnecessary or improper treatment if followed?

- Yes
  - Warning
- No
  - **#9.** Is there a good reason (e.g., new, stronger evidence will be published soon, changes to current recommendations are trivial or address very limited situations) to postpone updating the guideline?

- Yes
  - Deferral
- No
  - **#10.** An update should be initiated as soon as possible. List the expected date of completion of the update.

**STEP 5: Final outcome approval; Document Assessment & Review questions #11**

**#11.** Circulate this form, the new evidence, and a draft document for approval by the appropriate DSG. Once approved, a copy of this form should be placed behind the cover page of the current document on the website. Notify the original authors of the document about this review.
DOCUMENT ASSESSMENT AND REVIEW DEFINITIONS

*DEFINITIVE RECOMMENDATIONS* - Definitive means that the current recommendations address the relevant subject area so fully that it would be very surprising to identify any contradictory or clarifying evidence.

§SUFFICIENT RECOMMENDATIONS - Sufficient means that the current recommendations are based on consensus, opinion and/or limited evidence, and the likelihood of finding any further evidence of any variety is very small (e.g., in rare or poorly studied disease).

¶WARNING - A warning indicates that, although the topic is still relevant, there may be, or is, new evidence that may contradict the guideline recommendations or otherwise make the document suspect as a guide to clinical decision making. The document is removed from the website, and a warning is put in its place. A new literature search may be needed, depending on the clinical priority and resources.

**Document Assessment and Review Outcomes**

1. ARCHIVED - An archived document is a document that will no longer be tracked or updated but may still be useful for academic or other informational purposes. The document is moved to a separate section of our Web site, each page is watermarked with the phrase “ARCHIVED”.

2. ENDORSED - An endorsed document is a document that the DSG/GDG has reviewed for currency and relevance and determined to be still useful as guidance for clinical decision making. A document may be endorsed because the DSG/GDG feels the current recommendations and evidence are sufficient, or it may be endorsed after a literature search uncovers no evidence that would alter the recommendations in any important way.

3. DEFERRAL - A Deferral means that the clinical reviewers feel that the document is still useful and the decision has been made to postpone further action due to a number of reasons. The reasons for deferral should be found in the Document & Assessment Review form and on the document.

4. UPDATE - An Update means that the DSG/GDG recognizes that there is new evidence that makes changes to the existing recommendations in the guideline necessary but these changes are more involved and significant than can be accomplished through the Document Assessment and Review process. The DSG/GDG will rewrite the guideline at the earliest opportunity to reflect this new evidence. Until that time, the document will still be available as its existing recommendations are still of some use in clinical decision making.